

AWARD NUMBER: W81XWH-20-2-0022

TITLE: University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award

PRINCIPAL INVESTIGATOR: Naomi B. Haas, M.D.

CONTRACTING ORGANIZATION: Trustees of the University of Pennsylvania

REPORT DATE: OCTOBER 2023

TYPE OF REPORT: ANNUAL

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2023		2. REPORT TYPE Annual Report		3. DATES COVERED 15Sep2022 - 14Sep2023	
4. TITLE AND SUBTITLE University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award				5a. CONTRACT NUMBER W81XWH-20-2-0022	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Naomi B. Haas E-Mail:naomi.haas@penndmedicine.upenn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CLINICAL PRACTICES OF THE UNIVERSITY OF 3451 WALNUT ST STE 440A PHILADELPHIA PA 19104-6205				8. PERFORMING ORGANIZATION REPORT NUMBER #580467	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) ACRN AA	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S) CIN: GFEB5001149304900001	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of the University of Pennsylvania Abramson Cancer Center Kidney Cancer Research Consortium (PENN/ACC KCRC) award is to support the development of a data sharing infrastructure using the Prometheus platform so that Penn can collaborate with other members of the KCRC in a seamless method and participate in consortium phase I and II clinical trials. Over this year one of funding, we have helped to form a governance structure for all of the members, which includes an external advisory board. We have formalized a contracting and review process between Penn and the lead coordinating site, MD Anderson Cancer Center. Following the completion of these tasks, we have both presented three clinical trials for consideration of KCRC participation and we have submitted the first KCRC translational protocol to the Penn and Central Institutional Review Boards for imminent activation at Penn. We anticipate a robust accrual to this protocol and future participation and accrual to future KCRC treatment protocols. Finally, the KCRC website has been activated.					
15. SUBJECT TERMS KCRC=Kidney Cancer Research Consortium; MDACC=MD Anderson Cancer Center; Penn/ACC = University of Pennsylvania Abramson Cancer Center					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 63	19a. NAME OF RESPONSIBLE PERSON USAMRDC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4-5
4. Impact	9
5. Changes/Problems	11
6. Products	12
7. Participants & Other Collaborating Organizations	14
8. Special Reporting Requirements	15
9. Appendices	16

1. INTRODUCTION:

The goal of the University of Pennsylvania Abramson Cancer Center Kidney Cancer Research Consortium (PENN/ACC) participation is to meaningfully contribute to phase I and II clinical research in the context of multi-institutional collaborations with the 3 other member sites. Over the past year, while meeting monthly with other member sites, we have continued to form a governance structure for all of the groups and implemented a data sharing infrastructure which is based on the Prometheus platform. **We have activated our second consortium trial Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma and continued to enroll in “Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer” (MDA IRB# 2021-0379) in collaboration with Vanderbilt (a new member of KCRC) both through MDACC coordination. In the past year, we have presented a “Phase II study of total consolidative metastasis-and-primary directed therapy for renal cell carcinoma” responding to combination IO therapy. I have co-developed a concept with the consortium member, University of Michigan (Ulka Vaishampayan and Udit Singhal), “Phase II Trial of Single Agent Belzutifan or Pembrolizumab versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma”. This was approved for funding by the industry partner. We plan to bring this forward as future KCRC trial. Also, we continue to identify and pre-clinically test new CART targets for metastatic clear cell renal cancer. Further, we plan to open and accrue to 2 proposed trials from other consortium members. We anticipate that PENN/ACC participation in the Consortium will contribute patient numbers, intellectual input and translational research expertise to the KCRC and provide a critical platform for the co-development of renal cell carcinoma (RCC) clinical trials.**

2. KEYWORDS:

ACC= Abramson Cancer Center
API= Application Programming Interface
BIDMC= Beth Israel New England Deaconess Medical Center
DAG= Database and Applications Group
EAB= External Advisory Board
EDC= Electronic Data Capture
EHR= Electronic Health Record
GU= Genitourinary
IIT= Investigator Initiated Trial
IO= Immune checkpoint inhibitor combination
IRB= Institutional Review Board
KCRC= Kidney Cancer Research Consortium
MDACC= MD Anderson Cancer Center
PD1= Programmed death receptor 1
PENN= University of Pennsylvania
PSMA= Prostate Cancer Membrane Antigen
RCC= Renal Cell Carcinoma
TGFB= Transforming Growth Factor Beta
TKI= Tyrosine Kinase Inhibitor
UTSW= University of Texas Southwestern

4.ACCOMPLISHMENTS:

What were the major goals of the project?

Specific Aims

1. Design innovative clinical trials for the KCRC
2. Accrue at least 25 patients per year to KCRC trials
3. Perform translational research on samples obtained from KCRC trials

Major Task 1: Support an effective governance and management structure

Major Task 2: Endorse a harmonized protocol approval process

Major Task 3: Protocol participation, data automation, and monitoring platform

Major Task 4: Utilize Prometheus sample analysis infrastructure

Major Task 5: Create industry and philanthropic partnerships

Please refer to the next question for goals/tasks accomplished and timelines.

What was accomplished under these goals?

Specific Aims/Major Tasks	Timeline	Penn/ACC
Major Task 1: Design innovative clinical trials	Months	
Subtask 1: Submit for HRPO review	1-3	
Finalize cooperative agreements between institutions (contracting, IP agreements)	1-6	Cooperative contracting and intellectual property agreements between the PENN-ACC and MDACC were established months 1-6. KCRC Contractual Agreement was received from MDACC on 5/12/2020. PENN Lawyer, Kathleen Chen sent proposed changes 5/22/2020, MDACC routed to legal for signature 10/5/2020, The agreement was signed by ACC, MDACC, UTSW and BIDMC
Finalize data sharing infrastructure	1-6	The data sharing infrastructure was finalized in the past year: IRB Agreements were finalized between the MDACC coordinating center and the PENN/ACC. The biobanking protocol "Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer" (MDA IRB# 2021-0379) was the pilot protocol that identified and rectified details that impede activation. Major Task 3: Protocol participation, data automation, and monitoring platform:

		- By 10/20/20, the Application Programming Interface (API) was established. Under this Interface, the Penn electronic health record (EPIC) which contains data such as Demographics, Labs, Pathology, Vital Signs, Diagnosis, Staging, Performance Status as well as Tumor Measurements are linked to the Prometheus (with the same data det. Specifically, our ACC EHR and EDC set up “Hello World” and then an exchange test using anonymized patient data from a Penn Investigator initiated trial (IIT) was successfully implemented. Specific data are queried in EPIC Clarity and stored in a Penn Medicine database. - Additional tables are used to store protocol level data and the research labs that are collected for a given protocol. - API Request Client makes an API request with secure authentication for a subject(s) enrolled on a protocol(s) for a given date range. - API Endpoint API returns the data objects in JSON format to the client. <i>i.e. demographics, labs, vitals, etc.</i> Further API engagement will be required with implementation of KCRC clinical trials.
Subtask 3: Engage with Pharma and in-house team to develop clinical trial concepts	1-36	Proposed Penn Protocol Concepts: - Evaluating Lenvatinib and Pembrolizumab in sustaining progenitor exhausted CD8 T cells and durable T cell reinvigoration in renal cell carcinoma (Merck supported) - PSMA/TGFB CAR trial (Tmunity supported) Other CAR trials (Penn Philanthropy supported) Renal and other GU biobanking (Dibona, Mazzoleni and Penn Breakthrough Bike Challenge provide support) Phase II Trial of Single Agent Belzutifan or Pembrolizumab versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (Blaze) Phase II study of total consolidative metastasis-and-primary directed therapy for renal cell carcinoma in development. - Meetings 6/3/22 and 6/3/23 at ASCO with other KCRC sites at breakfast to engage pharma KCRC in person Retreats 11/5-6/22 and 7/14-15/23
Subtask 4: Develop and expand collaborations	1-36	A biomarker trial proposed by S. Haake: “Monitoring Disease Burden and Biology

with translational researchers and industry partners for correlative endpoints		Using Tumor Cell Free DNA in Metastatic Kidney Cancer” (MDA IRB# 2021-0379) • The trial was initiated with MDACC IRB and submitted to WCG IRB April 2021. • WCG IRB meeting was on 5/25/2021 • Subsequent submission to WCG IRB for ICD configuration in accordance with state • Received acknowledgement from Penn IRB to cede IRB review on 9/27/21. IRB application submitted to WCG for central approval on 10/5/21.
Subtask 5: Submit clinical trial concepts for review to KCRC	3-36	4 proposals have been reviewed: 1. Cryoablation of metastasis with ipilimumab and nivolumab 2. PSMA/TGFB CAR tumor agnostic trial 3. Evaluating Lenvatinib and Pembrolizumab in sustaining progenitor exhausted CD8 T cells and durable T cell reinvigoration in renal cell carcinoma 4. Phase II study of total consolidative metastasis-and-primary directed therapy for renal cell carcinoma. Presented at EAB meeting 7/15/2022. 5. Phase II Trial of Single Agent Belzutifan or Pembrolizumab versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (Blaze) on 10/3/23
Subtask 6: Participate in monthly KCRC meetings to vet and approve trials	1-36	The meetings are held monthly on the 3rd Tuesday of the month at 5pm EST Ongoing and Dr Haas has attended all but one meeting (July 19, 2022) and continuously since then.
Milestone(s) achieved:		
HRPO approval	3	
Contracting completed	6	See Major Task 1: Finalize cooperative agreements between institutions (contracting, IP agreements)
Data sharing infrastructure complete	6	See Finalize data sharing Infrastructure Major Task1
First clinical trial concept submitted	6	July 2020 - Cryoablation of metastasis with ipilimumab and nivolumab- KCRC committee voted no due to significant overlap with other trials open at the KCRC institutions PSMA/TGFB CAR trial to follow tumor agnostic trial- KCRC enthusiasm for this after preliminary data achieved in Penn tumor agnostic trial. KCRC tentatively approved development of “Evaluating Lenvatinib and Pembrolizumab in

		sustaining progenitor exhausted CD8 T cells and durable T cell reinvigoration in renal cell carcinoma” as a multi-center KCRC trial.
Major Task 2: Accrue at least 25 patients per year to KCRC studies		
Subtask 1: Reciprocally open KCRC trials at Clinical Trial Sites	1-36	Ongoing. Evaluating Lenvatinib and Pembrolizumab in sustaining progenitor exhausted CD8 T cells and durable T cell reinvigoration in renal cell carcinoma has been proposed and multi-center trial partially funded by Merck was submitted as a DOD clinical trial proposal but not funded. RO3. grant award planned. Initial planned accrual at MDACC and Penn/ACC. We just activated the Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma and plan to open Fortune: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma” (UMich).
Subtask 2: Optimize patient recruitment strategies	1-36	Ongoing. A patient kidney cancer conference (Judy Nicholson Kidney Cancer Foundation) was held at ACC/PENN on September 23, 2022. “Talk with the Experts-A Kidney Cancer Educational Symposium in Philadelphia” led by Dr. Haas and sponsored by the Judy Nicholson Kidney Cancer Foundation (JNKCF) included 6 KCRC consortium speakers was held 10/6/23. KCRC trials were highlighted in these patient focused symposiums. I also sponsored JNKCF in presentation of their foundation and proposed partnership with KCRC in monthly meeting (7/18/23). JNKCF was added to the KCRC website.
Milestone(s) achieved:		
Patient accrual rate achieved	1-36	“Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer” (MDA IRB# 2021-0379)” opened at Penn 10/21 (all KCRC sites are opening). 23 patients have enrolled in the trial. We have collected samples 51 times (4 tubes each time) for a total of 204 tubes. One patient consented to Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

Aim 3: Perform translational research on samples obtained from KCRC studies		
Subtask 1: Finalize correlative sample tracking infrastructure	1-6	See Major Task1, Subtask 4. "Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer" (MDA IRB# 2021-0379) biobanking trial activated and accruing. The institutional tracking infrastructure was implemented and works.
Subtask 2: Collect correlative samples	3-36	23 patients enrolled to Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer" (MDA IRB# 2021-0379) since October 2021.
Subtask 3: Transfer samples to site performing analyses	3-24	204 samples obtained for MDA IRB# 2021-0379 transferred to Vanderbilt to date.
Subtask 4: Perform analyses	12-36	Nothing to report
Subtask 5: Correlation to clinical data	12-36	RECIST forms from MDA IRB# 2021-0379 in EMR and submitted to both MDACC and to Vanderbilt
Milestone(s) achieved:		
Incorporation of translational research data into clinical trials	1-36	Nothing to Report

What opportunities for training and professional development has the project provided?

Judy Nicholson Kidney Cancer Symposium for patients occurred October 1, 2021 and Janaiya Reason created website for kidney cancer clinical trial support. Patient Symposium (Penn ACC and Judy Nicholson Kidney Cancer Foundation) on September 23, 2022. Drs. Haas, Mamtani, Lee and Narayan were all speakers. Dr S. Haake from Vanderbilt presented his DOD biobank project.

"Talk with the Experts-A Kidney Cancer Educational Symposium in Philadelphia" led by Dr. Haas and sponsored by the Judy Nicholson Kidney Cancer Foundation (JNKCF) included 6 KCRC consortium speakers was held 10/6/23. Speakers from Penn included N. Haas, V. Narayan, P. Pierorazio. Other KCRC speakers were K.Beckerman (Vanderbilt), H. Hammers (UTSW), U. Vaishapayan (UMich), E. Jonasch (MDACC)

How were the results disseminated to communities of interest?

PENN/Judy Nicholson Kidney Cancer Symposium for patients occurred October 1, 2021 and September 23,2022. **3rd Penn led symposium for patients was 10/6/23.**

What do you plan to do during the next reporting period to accomplish the goals?

Now that the Contracting, and Data Exchange Infrastructure is complete, the Penn/ACC major efforts are directed to opening clinical and translational trials and accruing patients to these trials. We will continue to work with Philanthropy and Industry to support pilot projects.

Dr. Haas is collaborating with Dr. Shevach (now at Duke under co-mentorship with Dr. George) and Drs. Phil Pierorazio and D. Lee (both urology) to complete protocol writing and obtain funding to support the Phase II study of total consolidative metastasis-and-primary directed therapy for renal cell carcinoma for patients with metastatic renal cancer who achieve deep response to IO therapy at 6 mo.

Dr. Huang is analyzing legacy samples to provide preliminary data for R03 funding for the above project.

Dr. Haas is meeting with Drs. June and Fraietta to apply pre-clinical data to support CAR trial for ccRCC

Dr Haas is working with Dr. Mamtani and Dr. George to develop a patient reported outcome and geocoding trial to gauge patient decision making about clinical trials in RCC.

Drs. Haas and George (Duke) are developing a program with Caris Scientific to provide competitive pilot funds for junior investigators to propose innovative biomarker trials.

Drs. Haas and George are developing a cross-cutting mentorship program between KCRC faculty and fellows and junior faculty at other K&C institutions to expand expertise across institutions.

Dr. Haas, Vaishampayan (U Mich), and Singhal (UMich) are writing the protocol for Phase II Trial of Single Agent Belzutifan or Pembrolizumab versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (Blaze).

Dr Narayan is now PI for VHL belzutifan registry trial (MDACC is lead site with Penn and Vanderbilt and Harvard as other sites).

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

The PI and other personnel involved in the Coordinating Center worked together to create an enabling infrastructure that will transform the way clinical trials are performed for patients with renal cell carcinoma.

We anticipate that the Prometheus Infrastructure will accelerate trial design, budgeting and approval, efficient risk-based monitoring and third party sample management will permit execution of novel trials.

Collaboration with now 6 institutions in the KCRC will permit more rapid initiation and accrual to clinical trials that would be difficult to complete at any single center. In addition, we have identified our catchment areas and underserved kidney cancer diseases and disease stages for clinical trials. Implementation of smaller trials in these populations will help provide valuable insights into these orphan diseases and will help provide objective information on the efficacy of therapies chosen to manage these diseases.

Renal Clear Cell Carcinoma Incidence Rates, Stratified by Race, Adults (18+), Both Sexes, University of Pennsylvania 2013-2017

Race/ Ethnicity	Stats	Year					
		2013	2014	2015	2016	2017	13'-17'
White	count	228	213	240	232	255	1168
	rate	75%	74%	85%	78%	79%	78%
Black/African American	count	64	58	37	54	54	267
	rate	21%	20%	13%	18%	17%	18%
Asian	count	6	7	3	5	7	28
	rate	2%	3%	1%	2%	2%	2%
Other/ Unknown	count	6	9	4	6	6	31
	rate	2%	3%	1%	2%	2%	2%

*Other/Unknown includes Unknown, American Indian, Native Hawaiian/Pacific Islander, & More than one race

KCRC

NAACCR AGE-ADJUSTED INCIDENCE RATES, 2000 US STANDARD POPULATION BY RACE/ETHNICITY KIDNEY AND RENAL PELVIS, ALL AGES, BOTH SEXES, PENNSYLVANIA, 2013-2017

Race/Ethnicity	Stat	Year					
		2013	2014	2015	2016	2017	2013-2017*
White	Rate	17.11	17.05	17.65	17.80	17.84	17.49
	Count	2,394	2,410	2,504	2,544	2,591	2,489
Black	Rate	22.94	23.69	22.61	21.42	21.89	22.49
	Count	327	337	325	320	327	327
Asian/Pacific Islander	Rate	8.24	6.84	5.86	7.61	3.89	6.36
	Count	24	26	22	29	17	24
American Indian/ Alaska Native	Rate	~	~	~	~	~	~
	Count	~	~	~	~	~	~
Hispanic	Rate	13.24	14.33	17.27	16.27	15.13	15.31
	Count	64	74	93	97	88	83
Non-Hispanic White	Rate	17.27	17.13	17.71	17.83	18.06	17.60
	Count	2,347	2,355	2,428	2,466	2,533	2,426
Non-Hispanic Black	Rate	23.67	24.17	23.42	22.08	22.22	23.10
	Count	322	328	321	313	316	320

(Accessed on 5-19-2021)

Results based on data submitted in December 2019.

* Average annual cases.

Rates are per 100,000 population and are age-adjusted by five-year age groups to the 2000 U.S. standard population based on single years of age.

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

~ Counts and rates are suppressed when fewer than 6 cases were reported for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

KQ

What was the impact on other disciplines?

Nothing to report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report this cycle.

5. CHANGES/PROBLEMS:

See below.

Actual or anticipated problems or delays and actions or plans to resolve them

The Covid-19 pandemic resulted in a hiring freeze at Penn/ACC. As a consequence, we lost much of our research staff which resulted in delays of clinical trial implementation. The research staff have largely been replaced. New program manager, two clinical research coordinators and two research nurses hired since 1/2022.

In 2023, we lost one research nurse but have recently hired a new research nurse who is undergoing training.

Changes that had a significant impact on expenditures

The covid pandemic slowed progress in the advancement of preclinical CAR T data into a pilot CAR T trial for renal cell. Thus the effort of Drs. Fraietta, Lal and Young were significantly reduced. It was necessary for Dr. Haas to put higher effort into moving the infrastructure (including readying clinical trial activation and enrollment of patient on to first therapeutic IIT) so her support was increased. We also await small amount of pending charges for this budget period.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Significant changes in use or care of human subjects

Nothing to Report

Significant changes in use or care of vertebrate animals

Not applicable

Significant changes in use of biohazards and/or select agents

Nothing to Report

6. PRODUCTS:

- **Publications, conference papers, and presentations**

Journal publications.

Dr. Narayan submitted a Trials in progress to GU ASCO 2024 for Neoadjuvant Pembrolizumab with or without Lenvatinib in high risk primary clear cell renal cancer.

We plan to submit preclinical data for T cell subsets (in anticipation of Phase II study of total consolidative metastasis-and-primary directed therapy for renal cell carcinoma for patients with metastatic renal cancer who achieve deep response to IO therapy at 6 mo.) to ASCO 2024 or AACR 2024.

Books or other non-periodical, one-time publications.

Nothing to report.

Other publications, conference papers and presentations.

Nothing to Report

- **Website(s) or other Internet site(s)**

KCRC website is now live.

Patient organizations such as the Judy Nicholson Kidney Cancer Foundation have been added to the website.

- **Technologies or techniques**

Nothing to Report

- **Inventions, patent applications, and/or licenses**

Nothing to Report

- **Other Products**

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name: **Naomi B. Haas, M.D.**

Project Role: Principal Investigator

Researcher Identifier: <https://orcid.org/0000-0001-8907-7968>

Nearest person month worked: 3.12

Contribution to Project: Dr. Haas is the PI and has participated in the monthly KCRC consortium calls. She has mentored Dr. Narayan and co-developed his proposed “phase II investigator-initiated trial with neoadjuvant pembrolizumab (PD-1) +/-lenvatinib (VEGFR-TKI) pre-nephrectomy followed by adjuvant pembrolizumab in locally advanced RCC.” Additionally, she meets weekly with the kidney cancer research staff to review proposals received and submitted to the KCRC.

Other effort

Dr Haas and Dr. Shevach (now at Duke in collaboration with Dr. George) with Dr Pierorazio (urology) and Dr. A. Huang (Immunology Penn) are writing the full protocol for a Phase II study of total consolidative metastasis-and-primary directed therapy for renal cell carcinoma for patients with metastatic renal cancer who achieve deep response to IO therapy at 6 mo.

Dr. Haas in collaboration with Drs. Vaishampayan and Singhal at UMich wrote the concept “Phase II Trial of Single Agent Belzutifan or Pembrolizumab versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma” which was approved for protocol development by Merck.

Dr. Haas has been working with Drs. June and Fraitta to use preclinical data for CAR T development in advanced RCC.

Name: **Vivek Narayan, M.D.**

Project Role: Co-Investigator

Nearest person month worked: 1

Contribution to Project: Dr. Narayan has developed a phase II investigator-initiated trial with neoadjuvant pembrolizumab +/-lenvatinib pre-nephrectomy followed by adjuvant pembrolizumab in locally advanced RCC. This is funded by Merck **and Dr. Narayan is applying for a R03 award.** This idea has been reviewed by the KCRC and is planned to be implemented at MDACC.

Dr. Narayan is submitting RO3 application to support infrastructure for Phase II “Evaluating Lenvatinib and Pembrolizumab in sustaining progenitor exhausted CD8 T cells and durable T cell reinvigoration in renal cell carcinoma” as a multi-center KCRC trial. Dr Mamtani is compiling Time study proposal for KCRC

Dr Narayan will be the PI for Penn in a just opening DOD funded multi-institutional registry trial of patients with VHL who start belzutifan therapy.

Name: ***Matt Doyle Replaced Janaiya Reason in 2022***

Project Role: PENN/ACC Institutional Clinical Trial Coordinator

Researcher Identifier (e.g. ORCID ID): NA

Nearest person month worked: 2.4

Contribution to Project: *Mr Doyle replaced Ms. Reason in this role as of May 2022, and coordinates the efforts between PENN/ACC/KCRC and the lead site, MDACC and the other participating sites including the following:*

- 1) Arrange the quarterly calls for the renal cancer clinical trials working group;
- 2) Continue to be on the monthly calls with the Kidney cancer clinical consortium and transmit information to the PENN/ACC investigators, with emphasis on new trial opportunities.
- 3) Keep an active list of renal cancer clinical trials ongoing in all sites in Kidney cancer clinical Consortium
- 4) Ms. Reason resigned her position as of May, 2022. Mr. Matthew Doyle has been hired as contractor to this position as of May 25, 2022.

Mr. Doyle is a hard worker and has worked with the MDACC coordinating center to both continue the above tasks and to open the Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma.

Mr. Doyle is a contractor and not salaried by the University of Pennsylvania.

Name: Elisabeth George -1.2

Project Role: Research Nurse

Researcher Identifier (e.g. ORCID ID): NA

Nearest person month worked: 1.2

Contribution to Project: *Ms. George reviewed the consent and protocol and assisted in the screening, assessment of AEs, administration and overall management of patients participating in Aravive Phase II trial of AVB-500 +/-cabozantinib +/- nivolumab in patients with metastatic clear cell RCC, and Dr. Narayan's neoadjuvant kidney cancer proposal, "Phase II investigator-initiated trial with neoadjuvant pembrolizumab (PD-1) +/-lenvatinib (VEGFR-TKI) pre-nephrectomy followed by adjuvant pembrolizumab in locally advanced RCC."*

Name: Maureen Didonato

Project Role: Clinical Trial Coordinator (data manager)

Researcher Identifier (e.g. ORCID ID): NA

Nearest person month worked: 2.64 cal

Contribution to Project: Data management for "Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer" (MDA IRB# 2021-0379)

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Yes, please see attached other support documents.

What other organizations were involved as partners? Nothing to Report

- Other.

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: Nothing to report.

QUAD CHARTS:

9. APPENDICES: Nothing to Report

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Title: ***(UPCC 15919): An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma***

Major Goals: To determine safety and efficacy using progression free survival of INBRX-105 in non small cell lung cancer, lymphoma, prostate cancer and melanoma. Aim 1: dose limiting toxicity; Aim2: progression free survival in these cancers.

Project Number: Ph1 INBRX-105

Source of Support: Inhibrix, Inc.

Name of PD/PI: Haas Role: PI

Sponsor Contact: Klaus M. Wagner

Primary Place of Performance: University of Pennsylvania

Project Period: 1/16/2020-6/30/2024 Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023	2024
Effort	0.24 Cal.	0.24 Cal.

Title: ***UPCC 09817:A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)***

Major Goals: To measure overall survival and disease free survival in patients with completely resected high risk clear cell renal cancer receiving pembrolizumab or placebo. Aim 1: disease free survival; Aim2: overall survival .

Project Number: MK-3475-564-00-Haas

Source of Support: Merck & Co., Inc.

Name of PD/PI: Haas Role: PI

Sponsor Contact: Ashley Buckley

Primary Place of Performance: University of Pennsylvania

Project Period: 6/19/2017-06/30/2024 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023	2024
Effort	0.12 Cal.	0.12 Cal.

Title: ***Safety/feasibility run-in cohort for randomized multi center open label Phase 2 trial of nivolumab + ipilimumab with or without Lipiodol:ethanol embolization for Stage 4 renal cell carcinoma with unresected primary***

Major Goals: To evaluate the safety of embolotherapy in patients with metastatic RCC receiving ICI therapy ; Secondary Objectives: 1.To investigate anti-tumor efficacy of ICI therapy in combination with immunostimulatory tumor embolization as measured by objective response rate ; 2.Characterize change in infiltrating immune cells in peripheral blood, primary and metastatic tumor sites before and after immunostimulatory embolization; 3.Characterize exosomal PD-L1 expression as a biomarker of response or resistance to immunotherapy.

Project Number: P30 CA016520

Source of Support: NIH

Name of PD/PI: Robert Vonderheide

Role: Pilot Co-PI with Dr. Soulen

Sponsor Contact: Krzysztof Ptak

Primary Place of Performance: University of Pennsylvania

Project Period: 12/1/19-11/30/23 Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.12 Cal.

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Title: ***University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award***

Major Goals: Aim 1: Design innovative clinical trials for the KCRC; Aim 2. Accrue at least 25 patients per year to KCRC trials; Aim 3. Perform translational research on samples obtained from KCRC trials.

Project Number: UT MDACC

Source of Support: Department of Army

Name of PD/PI: Haas Role: Site PI

Sponsor Contact: Amie Bunker

Primary Place of Performance: University of Pennsylvania

Project Period: 9/15/20-9/14/24 Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2024
Effort	1.8 Cal.

Title: ***Abramson Cancer Center Support Grant***

Major Goals: This grant supports the cancer research effort of the Abramson Cancer Center of the University of Pennsylvania.

Project Number: P30 CA016520

Source of Support: NIH

Name of PD/PI: Robert Vonderheide Role: Co-Leader of Cancer Therapeutics Program

Sponsor Contact: Krzysztof Ptak Primary Place of

Performance: University of Pennsylvania

Project Period: 12/1/20-11/30/25 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023	2024	2025
Effort	1.2 Cal.	1.2 Cal.	1.2 Cal.

Title: ***Phase 1 Study of PSMA-TGFBRDN CAR Modified T Cells in Patients with Advanced Castrate Resistant Prostate Cancer***

Major Goals: Determine the safety and feasibility of intravenous administration of lentivirally transduced CART-PSMA-TGF β RDN autologous cells with and without cyclophosphamide/fludarabine lymphodepleting chemotherapy in patients with advanced castrate resistant prostate cancer.

Project Number: RTrial 32816 (cohort 4)

Source of Support: Internal funding/Gift fund

Name of PD/PI: Carl June Role: Clinical PI

Sponsor Contact: *Angel McDev*

Primary Place of Performance: University of Pennsylvania

Project Period: 3/1/22-2/28/24 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023
Effort	0.6 Cal.

Title: ***Developing Engineered Cell Therapies for Metastatic Castrate Resistant Prostate Cancer to Increase Efficacy and Decrease Toxicity***

Major Goals: To unravel cell-cell communications in the TME that direct CAR T cell response and resistance to mCRPC and engineer bispecific CARs in T cells targeting heterogeneously expressed prostate cancer-associated antigens and aberrant glycosylation products

Project Number: 22TACT03

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Source of Support: Prostate Cancer Foundation

Name of PD/PI: Carl June Role: Co-Investigator

Sponsor Contact: Mark Patricu Primary Place of Performance:
University of Pennsylvania

Project Period: 2/10/23-2/9/26 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023-2024
Effort	0.6 Cal.

Title: (UPCC 28822): A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)

Major Goals: Assess the pathologic complete response (pCR) rate and minimal residual disease (MRD) rate with neoadjuvant olaparib and an LHRH agonist in patients with germline or somatic BRCA1/2 gene alterations.

Project Number: Haas - HCRN GU20-436

Project Period: 4/18/23-5/31/25

Source of Support: Hoosier Cancer Research Network, Inc

Name of PD/PI: Haas Role: PI Total Award Amount:

Sponsor Contact: Anita Camic

Primary Place of Performance: University of Pennsylvania

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023-2025
Effort	0.36 Cal.

Title: *Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma.*

Major Goals: To measure response rate, progression free survival and overall survival in patients with metastatic renal cancer receiving nivolumab followed by the addition of ipilimumab for progression. The primary endpoint is response rate in patients with clear cell RCC. Single cell RNA sequencing is performed in a cohort of patients with tumor at baseline and at progression to determine markers of resistance. Aim 1: overall response rate; Aim2: overall survival; Aim3: single cell RNA seq as predictor of response.

Project Number: GU16-260

Project Period: 9/1/17-06/30/24

Source of Support: Hoosier Cancer Research Network, Inc

Name of PD/PI: Haas Role: PI Total Award Amount:

Sponsor Contact: Robyn Lillie

Primary Place of Performance: University of Pennsylvania

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023
Effort	0.12 Cal.

Title: (UPCC 4820): Merck: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma After Prior PD-1/L1 and VEGF-Targeted Therapies (MK-6482-005-1525)

Major Goals: To compare MK-6482 to everolimus with respect to PFS per RECIST 1.1 as assessed by BICR. Hypothesis (H1): MK-6482 is superior to everolimus with respect to PFS per RECIST 1.1 by BICR.

Project Number: MK-6482-005-00

Source of Support: Merck & Co., Inc.

Name of PD/PI: Haas Role: PI

Sponsor Contact: Bradley, S'Leah

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Primary Place of Performance: University of Pennsylvania

Project Period: 4/30/2020-6/30/2024 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2024
Effort	0.12 Cal.

Title: ***UPCC 13816: A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta®) versus Sunitinib (Sutent®) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma***

Major Goals: To determine overall survival and progression free survival of a PDL-1 inhibitor in combination with a VEGFR TKI (axitinib) versus a VEGFR TKI (sunitinib) alone. Aim 1: progression free survival; Aim2: overall survival .

Project Number: B9991003

Project Period: 8/3/16-06/30/24

Source of Support: PFIZER INC.

Name of PD/PI: Haas

Role: PI

Total Award Amount:

Sponsor Contact: Paul Sanders

Primary Place of Performance: University of Pennsylvania

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023-2024
Effort	1.2 Cal.

PENDING:

Title: Phase II Randomized Clinical Trial of ONC392, a Novel CTLA-4 inhibitor in Advanced Pretreated Renal Cancer (RCC) in Combination with Tivozanib [CONCR trial]

Major Goals: 1. Primary Objective: To compare efficacy of tivozanib single agent and in combination with ONC392 in advanced RCC; 2. Secondary Objectives: 1) To assess the safety of ONC392 in combination with tivozanib in advanced RCC; 2) To compare response rates, progression free survival and overall survival. Correlative Objectives: 3) To evaluate the quality of life through patient reported surveys; 4) To evaluate pharmacokinetics and pharmacodynamics of ONC 392 in combination with tivozanib.

Project Number: KC220225

Name of PD/PI: Ulka Vaishampayan

Role: Co-Investigator

Sponsor: DOD through University of Michigan

Sponsor Contact: Vaishampayan, Ulka _____

Primary Place of Performance: University of Pennsylvania

Project Period: 10/1/23-9/30/26 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2024-2026
Effort	Cal.0.12

IN KIND: None

OVERLAP: None

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

COMPLETED:

Title: ***Abramson Cancer Center Support Grant***

Major Goals: Provide infrastructure for cancer research

Project Number: P30 CA016520

Source of Support: NIH

Name of PD/PI: Robert Vonderheide Role: Co-Leader of Cancer Therapeutics Program

Sponsor Contact: Henry P. Ciolino Primary Place of

Performance: University of Pennsylvania

Project Period: 12/1/10-11/30/20 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2021
Effort	1.2 Cal.

Title: ***A Phase 1/2 Dose-Escalation and Safety Study of ADXS31142 Alone and of ADXS31-142 in Combination with Pembrolizumab (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer***

Major Goals: To determine safety (dose-limiting toxicity) and overall response in patients with metastatic castrate resistant prostate cancer. A secondary endpoint is overall survival.

Project Number: ADXS142-03 Source of Support: Advaxis

Name of PD/PI: Haas Role: PI

Sponsor Contact: Emily Stevenson

Primary Place of Performance: University of Pennsylvania

Project Period: 5/11/15-6/30/21 Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.12 Cal.

Title: ***R2810-ONC-1423 Study: A First-in-Human Study of Repeat Dosing with REGN2810, A Monoclonal, Fully***

Major Goals: Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with other AntiCancer Therapies, in Patients with Advanced Malignancies

Project Number: R2810-ONC-1423

Source of Support: Regeneron Pharmaceuticals

Name of PD/PI: Haas Role: PI

Sponsor Contact: Collin M Strickland

Primary Place of Performance: University of Pennsylvania

Project Period: 1/29/16-1/28/19 Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2019
Effort	0.12 Cal.

Title: ***A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion and Extension Study***

Major Goals: To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Asn001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer

Project Number: ASN001-101

Source of Support: Asana Biosciences

Name of PD/PI: Haas Role: PI

Sponsor Contact: Sponsor contact: Pete L

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Primary Place of Performance: University of Pennsylvania

Project Period: 8/5/15-8/4/19 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2019
Effort	0.12 Cal.

Title: ***A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors***

Major Goals: To establish dose limiting toxicity of the glutaminase inhibitor CB839 in combination with nivolumab in metastatic clear cell renal cancer. Aim 1 dose limiting toxicity; Aim 2 progression free survival.

Project Number: CX-839-004

Source of Support: Calithera Biosciences

Name of PD/PI: Haas

Role: PI

Sponsor Contact: Susan David, MD Senior Director, Pharmacovigilance, Calithera Biosciences, Inc.

Primary Place of Performance: University of Pennsylvania

Project Period: 10/12/17-10/11/19 Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2019
Effort	0.12 Cal.

Title: ***A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy.***

Major Goals: To measure overall survival and disease free survival in patients with completely resected high risk clear cell renal cancer receiving pazopanib or placebo.

Project Number: VEG113387

Name of PD/PI: Haas

Role: PI

Source of Support: Novartis Pharmaceuticals Corporation

Sponsor Contact: Tamika Jones

Primary Place of Performance: University of Pennsylvania

Project Period: 3/14/11-5/13/20 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2020
Effort	0.12 Cal.

Title: ***(UPCC 07811): Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of RAD001 and hydroxychloroquine in patients with previously treated renal cell carcinoma***

Major Goals: To determine safety and efficacy using response rate and progression free survival of an autophagy inhibitor in combination with a mammalian target of rapamycin inhibitor in patients with metastatic clear cell renal cancer.

Project Number: CRAD001LUS174T

Source of Support: Novartis Pharmaceuticals Corporation

Name of PD/PI: Haas

Role: PI

Sponsor Contact: Gregory Mantalban

Primary Place of Performance: University of Pennsylvania

Project Period: 12/1/11-6/30/21 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2021
Effort	0.36 Cal.

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Title: ***The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma***

Major Goals: To predict the aggressiveness of chromophobe renal cancers. Aim 1. To determine the role of impairment of the glutathione salvage pathway in the pathogenesis and therapy of ChRCC. Aim 2. To determine the therapeutic impact of targeting glutathione biosynthetic pathways in ChRCC in vitro and in vivo. Aim 3. To identify molecular and metabolic determinants of the metastatic potential of ChRCC.

Project Number: R01 CA216922

Source of Support: NIH

Name of PD/PI: Haas; Henske

Role: Co-PI

Sponsor Contact: Michael G. Espe

Primary Place of Performance: University of Pennsylvania

Project Period: 1/15/18-12/31/19

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2020
Effort	0.36 Cal.

Title: ***A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma***

Major Goals: To determine overall response rate and progression free survival survival in patients with metastatic clear cell renal cancer receiving X4P-001 in combination with axitinib. Co-primary endpoint is safety. Aim 1: progression free survival; Aim2: overall response rate; Aim3: dose limiting toxicities.

Project Number: X4P-001-RCCA

Source of Support: X4 Pharmaceuticals, Inc

Name of PD/PI: Haas

Role: PI

Sponsor Contact: Michelle Barrick, Clinical Research Associate; Lu Gan MD, PhD, Medical Director

Primary Place of Performance: University of Pennsylvania

Project Period: 7/24/17-8/30/22

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.12 Cal.

Title: ***Planning grant for CARISMA – Cancer therapy risk-reduction with intensive systolic BP management***

Major Goals: To perform a Phase III randomized clinical trial to test the hypothesis that intensive systolic blood pressure lowering to a targeted of <120 mmHg, as compared to Usual Care, is well-tolerated and beneficial in cancer patients receiving AA-TKIs. It will provide the necessary and sufficient data to determine if an intensive blood pressure control strategy is well-tolerated and efficacious in patients receiving anti-angiogenic tyrosine kinase inhibitors.

Project Number: R34HL146927

Source of Support: NIH

Name of PD/PI: KY; Margulies

Role: Co-Investigator

Sponsor Contact: Patrice Desvigne-Nickens

Primary Place of Performance: University of Pennsylvania

Project Period: 8/1/19-7/31/22

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.12 Cal.

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Title: ***Exploiting Cholesterol Metabolism to Treat Primary and Metastatic Renal Carcinoma***

Major Goals: Specific Aims: 1A) Evaluation of SCARB1 effects on orthotopic and metastatic ccRCC.; 1B) Translating SCARB1 inhibition into future ccRCC treatments; 1C) Defining the mechanistic basis of SCARB1 effects on ccRCC cell growth. 2A) Evaluation of HSD3B7 effects on orthotopic and metastatic ccRCC. 2B) Defining the mechanistic basis of HSD3B7 inhibition-mediated ccRCC cell death.

Project Number: KC190080

Source of Support: Department of Defense

Name of PD/PI: Celeste Simon

Role: Co-Investigator

Sponsor Contact: Joshua D. McKea

Primary Place of Performance: University of Pennsylvania

Project Period: 9/30/20-9/29/22

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.36 Cal.

Title: ***Development and Testing of Circulating-Free Methylation DNA as a Prognostic Biomarker for Recurrent Kidney Cancer***

Major Goals: Aim 1: To evaluate the relationship between cfmeDNA and recurrence in patients with early-stage RCC treated with placebo. Aim 2: To evaluate the relationship between cfmeDNA and recurrence in patients with early-stage RCC treated with pazopanib.

Project Number: KCRP

Source of Support: Department of Defense

Name of PD/PI: Toni Choueiri

Role: Co-Investigator

Sponsor Contact: Karen Eato

Primary Place of Performance: University of Pennsylvania

Project Period: 9/31/2019-9/30/22

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.6 Cal.

Title: ***Metabolic Reprogramming of the CAR T cell Epigenome***

Major Goals: We will develop next generation therapies with CAR T cells, involving innovative combinations of metabolic as well as epigenetic modifiers of the aforementioned checkpoint switches and genetic technology to be tested in rigorous preclinical models.

Project Number: ACGT

Source of Support: Alliance for Cancer Gene Therapy

Name of PD/PI: Joe Fraietta

Role: Co-Investigator

Sponsor Contact: Margaret Ciani

Primary Place of Performance: University of Pennsylvania

Project Period: 2/1/20-1/31/23

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022	2023
Effort	0.84 Cal.	0.84 Cal.

Other Support

Name of Individual: Naomi B Haas

Commons ID: NAOMHAAS

Title: ***Epigenetic mechanisms of drug resistance in renal cell carcinoma***

Major Goals: To determine the role of epigenetics in resistance mechanisms to RTKIs in ccRcc, to assess the epigenomic signature associated with resistance phenotype, and to develop novel therapeutic strategies to induce epigenetic reprogramming and consequently overcome loss of response to RTKIs.

Aim1: Determine whether EZH2 and AR tumor expression is associated with shorter recurrence-free survival in RCC patients treated with RTKIs in the adjuvant setting. Aim2: Determine circulating levels of mir-26a in RCC patients treated with RTKIs. Aim3: Determine circulating levels of hK2 in RCC patients treated with RTKIs

Project Number: R01 CA224342

Source of Support: NIH

Name of PD/PI: Pili, R., Hollenhorst, P., Haas, N

Role: Co-PI

Sponsor Contact: Sudhir B Kondapaka

Primary Place of Performance: University of Pennsylvania

Project Period: 9/1/17-1/31/23

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023
Effort	0.96 Cal.

Title: ***Emerging Translational Center of Excellence in Prostate Cancer: Prostate Cancer African American Disparities (PCAAD)***

Major Goals: Aim 1. Develop a Biobank of Biospecimens from African American and white patients with Prostate Cancer

Project Number: Prostate TCE

Source of Support: Breakthrough Bike Challenge Foundation

Name of PD/PI: Penning; Haas

Role: Co-Investigator

Sponsor Contact: Bart Ziemski;

Primary Place of Performance: University of Pennsylvania

Project Period: 4/1/21-3/31/23

Total Award Amount

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023
Effort	0.01 Cal.

Title: ***Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma***

Major Goals: To determine if dynamic contrast enhancement changes in MRI are predictive of response to pazopanib in patients with metastatic clear cell renal cancer. This aim will correlate with progression free survival. Aim 1: DCE measurement correlating with PFS.

Project Number: GSK CT (UPCC 34809)

Source of Support: GLAXOSMITHKLINE

Name of PD/PI: Haas

Role: PI

Sponsor Contact: Kristin Haines

Primary Place of Performance: University of Pennsylvania

Project Period: 08/30/2010-6/30/23

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023
Effort	0.12 Cal.

Current and Pending Support

Investigator: Vivek K Narayan

Current Support

Project Title: UPCC 02818 (IIT Pfizer Phase 1/1b Avelumab + Gemcitabine for RCC w/ Sarcomatoid Diff)

Initial Submission Notification

Time Commitment: > 0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: PFIZER INC.

Sponsor Award Number: Narayan-WI224974

Agency Contact: Zhou Yang, Project Leader

Performance Period: 03/16/2018 - 06/30/2024

Level of Funding:

Project Goals: To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.

Overlap: There is no overlap with current project

Project Title: An Open Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel- Lindau Disease-Associated Renal Cell Carcinoma

Time Commitment: > 0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: PELOTON THERAPEUTICS, INC.

Sponsor Award Number: PT2977-202

Agency Contact: Holly McDonald, Project Leader

Performance Period: 08/15/2018 - 06/30/2024

Level of Funding:

Project Goals: This study is designed to investigate belzutifan as a treatment for VHL disease-associated RCC.

Overlap: There is no overlap with current project

Project Title: (UPCC 20818): A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors

Time Commitment: > 0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: PFIZER INC.

Sponsor Award Number: B9991032

Agency Contact: Zhou Yang, Project Leader

Performance Period: 09/26/2018 - 06/30/2024

Level of Funding:

Project Goals: Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.

Overlap: There is no overlap with the current project

Project Title: The cell and gene therapy toolkit for junior faculty

Time Commitment: > 0.12 Cal

PD/PI: Elizabeth Hexner Role: Co-I

Supporting Agency: NATIONAL CANCER INSTITUTE/NIH/DHHS

Sponsor Award Number: 1-UE5-CA-246744-01

Agency Contact: ZAHIR, NASTARAN

Performance Period: 04/01/2020 - 03/31/2024

Level of Funding:

Project Goals: Our objective is to train a cadre of junior faculty level NCI-funded investigators in critical skills related to cell and gene therapy to accelerate their work.

Overlap: There is no overlap with the current project

Project Title: (UPCC 21819): PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer with DNA Repair Defects

Time Commitment: 0.25 Cal

PD/PI: Vivek K Narayan

Supporting Agency: JANSSEN RESEARCH FOUNDATION

Sponsor Award Number: 64091742PCR2006

Agency Contact:

Performance Period: 06/03/2020 - 06/30/2024

Level of Funding:

Project Goals: This study will evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer.

Overlap: There is no overlap with the current project

Project Title: CART-PSMA-TGFBRDN-02: A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Metastatic Castration Resistant Prostate Cancer

Time Commitment: >0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: TMUNITY THERAPEUTICS, INC

Sponsor Award Number: CART-PSMA-TGFBRDN-02

Agency Contact: Thomas Fountaine, MD

Performance Period: 09/01/2020 - 06/30/2025

Level of Funding:

Project Goals: Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGF β RDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.

Overlap: There is no overlap with the current project

Project Title: University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award

Time Commitment: 0.36 Cal

PD/PI: Naomi B Haas MD Role: Co-I

Supporting Agency: DEPARTMENT OF THE ARMY

Sponsor Award Number: W81XWH2020022

Agency Contact: Amie Bunker

Performance Period: 09/15/2020 - 09/14/2024

Level of Funding:

Project Goals: Aim 1: Design innovative clinical trials for the KCRC; Aim 2. Accrue at least 25 patients per year to KCRC trials; Aim 3. Perform translational research on samples obtained from KCRC trials.

Overlap: There is no overlap with the current project

Project Title: (UPCC 15820): A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Time Commitment: > 0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: JANSSEN RESEARCH AND DEVELOPMENT, LLC

Sponsor Award Number: Narayan-67652000PCR3002

Agency Contact: Study Contact 844-434-4210

Performance Period: 02/01/2021 - 12/31/2028

Level of Funding:

Project Goals: The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Overlap: There is no overlap with the current project

Project Title: Phenotyping the Social Determinants of Cardiovascular Health in Cancer Patients and Survivors (Clinical Project)

Time Commitment: >0.1 Cal

PD/PI: Bonnie Ky MD Role: Co-I

Supporting Agency: AMERICAN HEART ASSOCIATION

Sponsor Award Number: KY - AHA

Agency Contact: 1-888-478-7653

Performance Period: 07/01/2021 - 06/30/2025

Level of Funding:

Project Goals: The overall objective of our proposed research network is to comprehensively define and mitigate the biologic, structural and personal determinants of racial disparities in high cardiovascular risk cancer patients and survivors.

Overlap: There is no overlap with the current project

Project Title: Understanding and Reducing Racial Disparities in High Risk Cardio-Oncology Communities

Time Commitment: >0.1 Cal

PD/PI: Bonnie Ky MD Role: Co-I

Supporting Agency: AMERICAN HEART ASSOCIATION

Sponsor Award Number: AHA AWARD

Agency Contact: 1-888-478-7653

Performance Period: 07/01/2021 - 06/30/2025

Level of Funding:

Project Goals: The overall objective of our proposed research network is to comprehensively define and mitigate the biologic, structural and personal determinants of racial disparities in high cardiovascular risk cancer patients and survivors.

Overlap: There is no overlap with the current project

Project Title: (UPCC 09821): Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer
Time Commitment: >0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: REGENERON PHARMACEUTICALS, INC.

Sponsor Award Number: R4336-ONC-20104 - Narayan

Agency Contact: Clinical Trials Administrator 844-734-6643

Performance Period: 11/12/2021 - 10/31/2024

Level of Funding:

Project Goals: The primary objective of the study is to assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination with cemiplimab. To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by objective response rate (ORR) per modified Prostate Cancer Working Group (PCWG3) criteria. To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by ORR per modified PCWG3 criteria

Overlap: There is no overlap with the current project

Project Title: (UPCC 11821): A Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb(R)20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer

Time Commitment: Dependent on enrollment

PD/PI: Vivek K Narayan

Supporting Agency: XENCOR, INC.

Sponsor Award Number: XmAb20717-04 - Narayan

Agency Contact: Jolene Shorr

Performance Period: 11/29/2021 - 11/28/2023

Level of Funding:

Project Goals: This Phase 2 study will investigate the safety and clinical activity of XmAb20717 alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with at least 2 prior lines of anticancer therapy.

Overlap: There is no overlap with the current project

Project Title: (UPCC 21121): An Open-Label Study For Continued Treatment Access For Participants From The B9991032 Avelumab Study

Time Commitment: >0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: PFIZER INC.

Sponsor Award Number: B9991046 - Narayan

Agency Contact:

Performance Period: 04/22/2022 - 04/30/2025

Level of Funding:

Project Goals: The purpose of the continuation sub-study is to provide continued treatment access for participants from the B9991032 Parent Study who are deriving benefit from study treatment as judged by the investigator.

Overlap: There is no overlap with the current project

Project Title: (UPCC 10821): A Phase 1/2 Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1) in Patients with Metastatic Castration-resistant Prostate Cancer

Time Commitment: >0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: REGENERON PHARMACEUTICALS, INC.

Sponsor Award Number: Narayan - R5678-ONC-1879

Agency Contact: Elizabeth Miller

Performance Period: 05/09/2022 - 11/30/2023

Level of Funding:

Project Goals: The primary objectives of the study in Dose Escalation are to evaluate safety, tolerability, and pharmacokinetics (PK) of REGN5678 alone and in combination with cemiplimab and in Dose Expansion are to assess efficacy, as measured by objective response rate (ORR) per modified Prostate Cancer Working Group 3 (PCWG3) criteria, of REGN5678 in combination with cemiplimab.

The secondary objectives of the study in Dose Escalation are to assess efficacy, as measured by ORR per modified PCWG3 criteria, of REGN5678 in combination with cemiplimab and in Dose Expansion are to characterize the safety profile in each expansion cohort and to characterize the PK of REGN5678 in combination with cemiplimab. Secondary objectives in both Dose Escalation and Dose Expansion are to assess efficacy of REGN5678 in combination with cemiplimab, as measured by additional criteria and to assess immunogenicity of REGN5678 in combination with cemiplimab.

Overlap: There is no overlap with the current project

Project Title: (UPCC 19821): A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer

Time Commitment: >0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: JANSSEN RESEARCH AND DEVELOPMENT, LLC

Sponsor Award Number: 75229414MPC1001 - Narayan

Agency Contact: Study Contact

Performance Period: 06/08/2022 - 03/31/2026

Level of Funding:

Project Goals: The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).

Overlap: There is no overlap with the current project

Project Title: (UPCC 17822): A Phase 1, Multi-center, Open-label, Dose finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC 94676 in Subjects with Metastatic Castration-resistant Prostate Cancer

Time Commitment: >0.12 Cal

PD/PI: Vivek K Narayan

Supporting Agency: CELGENE CORPORATION

Sponsor Award Number: CC-94676-PCA-001 - Narayan

Agency Contact: Rachel Schmidt

Performance Period: 10/20/2022 - 10/31/2027

Level of Funding:

Project Goals: The purpose of this study is to determine the recommended Phase 2 dose (RP2D) regimen of CC-94676 in patients with metastatic castration-resistant prostate cancer.

Overlap: There is no overlap with the current project.

Project Title: (UPCC 18822): Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma
Time Commitment: 0.6 Cal (per patient enrollment)
PD/PI: Vivek K Narayan
Supporting Agency: MERCK & CO., INC.
Sponsor Award Number: Narayan - 60918
Agency Contact: Andy Yan
Performance Period: 01/30/2023 - 11/30/2027
Level of Funding:
Project Goals: To evaluate the role of lenvatinib and pembrolizumab in sustaining progenitor exhausted CD8 T cells and durable T cell reinvigoration in renal cell carcinoma
Overlap: There is no overlap with the current project.

Project Title: Developing Engineered Cell Therapies for Metastatic Castrate Resistant Prostate Cancer to Increase Efficacy and Decrease Toxicity
Time Commitment: 0.6 Cal
PD/PI: Carl H June Role: Co-I
Supporting Agency: PROSTATE CANCER FOUNDATION
Sponsor Award Number: 22TACT03
Agency Contact: Audrey Gardner
Performance Period: 02/10/2023 - 02/09/2026
Level of Funding:
Project Goals: To unravel cell-cell communications in the TME that direct CAR T cell response and resistance to mCRPC and engineer bispecific CARs in T cells targeting heterogeneously expressed prostate cancer-associated antigens and aberrant glycosylation products
Overlap: There is no overlap with project

Project Title: The CARDiovascular Risk Evaluation in Men with Prostate Cancer Study (CARE-PC): Initial Pilot Feasibility Study to Assess Patient Awareness and Risk Mitigation
Time Commitment: 0.6 Cal
PD/PI: Vivek K Narayan
Supporting Agency: NATIONAL COMPREHENSIVE CANCER NETWORK (MYOVANT SCIENCES)
Sponsor Award Number: ONCOLOGY RESEARCH PROGRAM AWARD (N/A)
Agency Contact: Patricia White
Performance Period: 05/09/2023 - 05/08/2024
Level of Funding:
Project Goals: Through this proposal, we will develop a novel, web-based application that has functionalities to educate patients on CV risk, provide personalized estimates of individual CV risk, and collect data to better understand both the burden of CV risk across the prostate cancer treatment spectrum and the gaps in access to adequate treatment of CV risk factors.
Overlap: There is no overlap with project

Pending Support

None

Previous Support

Project Title: UPCC 18816: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors
Time Commitment: 0.0 Cal
Supporting Agency: MERCK & CO., INC.
Name of PD/PI: Vivek Narayan
Sponsor Award Number: MK-8628-006-00
Agency Contact: Contact information is only displayed when the study is recruiting subjects
Performance Period: 08/12/2016 - 08/11/2018
Level of Funding:
Project Goals: Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.

Project Title: ACS Institutional Research Grant
Time Commitment: 0.0 Cal
Supporting Agency: AMERICAN CANCER SOCIETY
Name of PD/PI: Vivek Narayan
Sponsor Award Number: IRG-16-188-38
Agency Contact: Cecilia Scavelli, Associate Director for Research Administration, Abramson Cancer Center
Performance Period: 01/01/2017 - 12/31/2020
Level of Funding:
Project Goals: Demonstrated a new engineering technique that, because it is less toxic to the T cells, could enable a different mechanism for altering the way they recognize cancer.

Project Title: UPCC 04817: A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC)
Time Commitment: 0.24 Cal
Supporting Agency: GLAXOSMITHKLINE
Name of PD/PI: Vivek Narayan
Sponsor Award Number: 204697-Narayan-827302
Agency Contact: Curt Moyer, Project Leader
Performance Period: 05/18/2017 - 12/31/2021
Level of Funding:
Project Goals: This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B).

Project Title: AUA/UCF Research Scholar Award 2017 Comprehensive Peripheral Blood Immune Cell and Circulating Tumor Cell Profiling for the Prediction of Response to Novel Immunotherapies in Renal Cell Carcinoma
Time Commitment: 0.0 Cal
Name of PD/PI: Vivek Narayan
Supporting Agency: AMERICAN UROLOGICAL ASSOCIATION FOUNDATION
Sponsor Award Number: N/A
Agency Contact: Krystal Brinson

Performance Period: 07/01/2017 - 06/30/2019

Level of Funding:

Project Goals: The goal of this study is to evaluate early predictors of clinical response to anti-PD1 immunotherapies in patients with advanced renal cell carcinoma.

Project Title: (UPCC 05818): A phase I/II study to evaluate the safety, pharmacodynamics and efficacy of atezolizumab in combination with entinostat and bevacizumab in patients with advanced renal cell carcinoma

Time Commitment: 0.24 Cal

Name of PD/PI: Vivek Narayan

Supporting Agency: INDIANA UNIVERSITY (GENENTECH, INC./F. HOFFMAN-LA ROCHE)

Sponsor Award Number: Narayan-IUSCC-0574 (ML39352) (N/A)

Agency Contact: Lina Segó

Performance Period: 05/17/2018 - 05/16/2021

Level of Funding:

Project Goals: The major goals of this investigator-initiated project are to conduct a phase ½ clinical trial of a novel combination treatment strategy for immunotherapy-refractory metastatic renal cell carcinoma.

Project Title: Evaluating Resistance Mechanisms and Enhancing Efficacy of PSMA-directed/TGF-insensitive CAR-T Cells in Advanced Prostate Cancer

Time Commitment: 2.4 Cal

Name of PD/PI: Vivek Narayan

Supporting Agency: PROSTATE CANCER FOUNDATION

Sponsor Award Number: 18YOUNG16

Agency Contact: Audrey Gardner

Performance Period: 08/06/2018 - 08/06/2022

Level of Funding:

Project Goals: The major goals of this project are: 1) to evaluate tumor tissue-based adaptive resistance mechanisms via comprehensive phenotyping of tumor-infiltrating T cells and phenotyping of the prostate cancer microenvironment *in situ*; and 2) to evaluate peripheral blood biomarkers of resistance via longitudinal characterization of circulating tumor material and T cell subtypes for patients treated with PSMA-redirected CAR-T therapy.

Project Title: Penn / NCCN Pre-visit Prostate Cancer Education Pilot

Time Commitment: 0.0 Cal

Name of PD/PI: Vivek Narayan

Supporting Agency: NATIONAL COMPREHENSIVE CANCER NETWORK

Sponsor Award Number: NCCN EDUCATION PILOT

Agency Contact: Dorothy Shead

Performance Period: 06/01/2021 - 05/31/2022

Level of Funding:

Project Goals: To evaluate the feasibility and acceptance of a pre-visit prostate cancer educational brochure for new prostate cancer patients to medical oncology or urology.

Project Title: UPCC 05817: A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men with Metastatic Castration-Resistance Prostate Cancer (Ca209-650)

Time Commitment: 0.24 Cal

Name PD/PI: Vivek K Narayan

Supporting Agency: Bristol-Myers Squibb Company

Sponsor Award Number: UPCC 05817

Agency Contact: Katie Joyce

Performance Period: 04/01/2017-08/22/2020

Level of Funding:

Project Goals: The major goals of this project are to conduct a phase 2 clinical trial of a combination immunotherapeutic strategy for treatment-refractory metastatic prostate cancer.

Title: Planning Grant for CARISMA - Cancer therapy Risk-reduction with Intensive Systolic BP Management

Time Commitment: 0.3 Cal

Name of PD/PI: Bonnie, Ky, MD MSCE Role: Co-I

Supporting Agency: NIH/NHLBI

Sponsor Award Number: 5R34HL146927-02

Contracting/Grants Officer:

Performance period: 08/01/2019 – 07/31/2021

Level of funding:

Project Goals: The goal is to determine if an intensive blood pressure control strategy is well-tolerated and efficacious in patients receiving anti-angiogenic tyrosine kinase inhibitors.

Current and Pending Support

Investigator: Regina M Young

Current Support

Project Title: Engineering the next generation of T cells

Time Commitment: 0.24 calendar months

Supporting Agency: NATIONAL CANCER INSTITUTE/NIH/DHHS

Sponsor Award Number: 1-U54-CA-244711-01

Agency Contact: Justin Birken

Performance Period: 09/25/2019 - 08/31/2024

Level of Funding:

Name of PD/PI: June Role: Co-Investigator

Project Goals: The purpose of this U54 is to employ immuno-engineering principles to design more durable, accessible, and less toxic immunoprevention and immunotherapy strategies. The focus of our U54 entitled "Engineering the next generation of T cells" is on developing next-generation gene-editing or modification of immune cells to improve persistence in vivo, control and manipulate the immune system to reduce off-target toxicities and enhance anti-tumor effectiveness of adoptive cell therapy.

Overlap: None

Project Title: University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award

Time Commitment: 0.36 calendar

Supporting Agency: DEPARTMENT OF THE ARMY

Sponsor Award Number: W81XWH2020022

Agency Contact: Amie Bunker

Performance Period: 09/15/2020 - 09/14/2024

Level of Funding:

Name of PD/PI: Haas Role: Co-Investigator

Project Goals: Aim 1: Design innovative clinical trials for the KCRC

Aim 2. Accrue at least 25 patients per year to KCRC trials

Aim 3. Perform translational research on samples obtained from KCRC trials

Overlap: None

Project Title: Developing Engineered Cell Therapies for Metastatic Castrate Resistant Prostate Cancer to Increase Efficacy and Decrease Toxicity

Time Commitment: 2.4 calendar

Supporting Agency: PROSTATE CANCER FOUNDATION

Sponsor Award Number: 22TACT03

Agency Contact: Audrey Gardner

Performance Period: 02/10/2023 - 02/09/2026

Level of Funding:

Name of PD/PI: June Role: Co-Investigator

Project Goals: To unravel cell-cell communications in the TME that direct CAR T cell response and resistance to mCRPC and engineer bispecific CARs in T cells targeting heterogeneously expressed prostate cancer-associated antigens and aberrant glycosylation products.

Overlap: None

Project Title: Parker Institute for Cancer Immunotherapy Project Award

Time Commitment: 7.8 calendar

Supporting Agency: Parker Institute for Cancer Immunotherapy

Sponsor Award Number: CJ10, CJ11, CJ12 & CJ13

Agency Contact: Sara Coblin

Performance Period: 01/01/2023 – 12/31/2023

Level of Funding:

Name of PD/PI: June Role: Co-Investigator

Project Goals: Define T cell exclusion mechanisms in pancreatic cancer liver metastasis

Overlap: None

Pending Support

Project Title: Kite Pharma- University of Pennsylvania Alliance

Time Commitment: 4.2 calendar

Supporting Agency: Kite Pharma

Sponsor Award Number: 2023-24 JUNE LAB

Agency Contact: Heather Johnson

Performance Period: 12/01/2023 - 11/30/2024

Level of Funding:

Name of PD/PI: June Role: Co-Investigator

Project Goals:.

Overlap: Effort will be reduced in the 1st month (December) because of Parker funding, in 2024 Parker funding will end and full effort will be applied

Previous Support

Project Title: Penn-Incyte Alliance

Time Commitment: 1.2 calendar

Supporting Agency: INCYTE CORPORATION

Sponsor Award Number: Incyte Alliance

Agency Contact: Harry Atkins

Performance Period: 02/01/2017 - 06/30/2020

Level of Funding:

Name of PD/PI: Albelda Role: Co-Investigator

Project Goals: The purpose of this collaboration between Penn and Incyte is to mobilize skills, knowledge and expertise for developing a focused and coordinated approach to cancer immunotherapy.

Overlap: None

Project Title: Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer

Time Commitment: 0.6 calendar

Supporting Agency: STAND UP TO CANCER

Sponsor Award Number: SU2C #RT6162

Agency Contact: Michael Stewart

Performance Period: 02/01/2019 - 11/30/2022

Level of Funding:

Name of PD/PI: June Role: Co-Investigator

Project Goals: Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer

Overlap: None

Project Title: Determinants of CD8+ T Cell Aging and Reduced Function in B Cell Cancer

Time Commitment: 0.6

Supporting Agency: NATIONAL INSTITUTE ON AGING/NIH/DHHS

Sponsor Award Number: 1-U01-AG-066100-01

Agency Contact: Justin Birken;

Performance Period: 06/15/2019 - 05/31/2022

Level of Funding:

Project Goals:

Overlap: None

Current and Pending Support

Investigator: JOSEPH A FRAIETTA

Current Support

Project Title: EVALUATION OF ANTI-TUMOR FUNCTION AND TOXICITY OF NOVEL CAR T CELLS

Time Commitment: 0.12

Supporting Agency: CARTOGRAPHY BIOSCIENCES, INC.

Sponsor Award Number: N/A

Agency Contact:

Performance Period: 11/01/2022 - 11/01/2024

Level of Funding:

Project Goals: This project will focus on production of CAR T cells using novel single-chain variable fragments (scFvs) and/or camelid heavy-chain variable domain (VHH)-based binders specific for various tumor antigens that have been developed and characterized by Cartography Bio.

Overlap: None

Role: PI

Project Title: University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award

Time Commitment: 0.36

Supporting Agency: Department of Army

Sponsor Award Number: W81XWH2020022

Agency Contact: Amie Bunker

Performance Period: 9/15/20-9/14/24

Level of Funding:

Project Goals: Aim 1: Design innovative clinical trials for the KCRC; Aim 2. Accrue at least 25 patients per year to KCRC trials; Aim 3. Perform translational research on samples obtained from KCRC trials.

Overlap: None

PI: Naomi Haas

Role: Co-Investigator

Project Title: Linking insertional mutagenesis and cell function to improve CAR T cell therapy

Time Commitment: 0.96

Supporting Agency: NATIONAL CANCER INSTITUTE/NIH/DHHS (NATIONAL INSTITUTES OF HEALTH)

Sponsor Award Number: 1-R01-CA-241762-01

Agency Contact: Lori Henderson,

Performance Period: 06/01/2019 - 04/30/2024

Current Support

Overlap:

Overlap: None

Project Title: Genetic identification of potential drug targets for benign prostatic hyperplasia (*PI: Daniel J Lee*)
Time Commitment: 0.6

Supporting Agency: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (NATIONAL CANCER INSTITUTE/NIH/DHHS)
Sponsor Award Number: N/A (Icahn School of Medicine at Mount Sinai | National Cancer Institute/NIH/DHHS)
Agency Contact: Joseph Vinci
Performance Period: 05/01/2023 - 04/30/2028
Level of Funding:
Project Goals: Identify genetic variants and genes associated with benign prostatic hyperplasia using genome wide association studies of large national datasets, determine in which cell types BPH-associated genetic elements function, and evaluate the potential of the identified genes as drug targets for BPH.
Overlap: None

Project Title: Patient-centered intervention to minimize surgical disparities in localized prostate cancer patients (*Sumedha Chhatre, MD*)
Time Commitment: 1.2
Supporting Agency: NATIONAL INSTITUTES OF HEALTH
Sponsor Award Number: N/A
Agency Contact: Angela D Thrasher
Performance Period: 12/01/2023 - 11/30/2028
Level of Funding:
Project Goals: Study objective is to assess the effectiveness of multilevel (patient and physician) intervention using the SDMP model in reducing racial disparities in surgery treatment and outcomes in African American and White patients with intermediate or high risk localized PCa. Patient level intervention includes web-based educational materials, including 'introduction to SDM concepts', and preference assessment using Preferences for Prostate Cancer Care (PreProCare) a web-based preference assessment tool
Overlap: None

Previous Support

Title: Urine-based Biomarkers for Detection and Risk Stratification of Bladder Cancer (*Daniel J Lee*)
Time Commitments: <0.12 calendar
Supporting Agency: University of Pennsylvania Department of Surgery
Address: 3400 Spruce St # 4, Philadelphia, PA 19104
Contracting/Grants Officer: Aisling McCormick,

Performance Period: 7/1/2020 – 6/30/2022
Level of funding:
Project Goals and Aims: Evaluating use of a nanopore platform to detect and diagnose bladder cancer, and improve risk stratification of bladder cancer
Overlap: None

Title: Exploiting Cholesterol Metabolism to Treat Primary and Metastatic Renal Carcinoma (PI: Simon)

Time Commitments: 0.36 calendar

Supporting Agency: Department of Defense Congressionally Directed Medical Research Programs, Kidney Cancer Research Program KC190080

Address: 1077 Patchel Street, Fort Detrick, MD 21702-5024,

Contracting/Grants Officer: Joshua D. McKean Grants Officer,

Performance Period: 7/1/2020 – 9/29/2022

Level of funding:

Project Goals and Aims: Characterizing and understanding the mechanisms of cholesterol metabolism, and identify novel therapeutic approaches for localized and metastatic renal cell carcinoma.

Overlap: None

Title: Learning Health Systems Mentored Career Development Program (PI: Kimmel, S/Asch, D)

Time Commitments: 9.0 calendar

Supporting Agency: Agency for Healthcare Research and Quality, 1K12 HS026372

Address: 5600 Fishers Ln #7, Rockville, MD 20857

Contracting/Grants Officer: Gabrielle Ostapovich, University of Pennsylvania,

Performance Period: 09/30/2019-09/29/2021

Level of funding:

Project Goals and Aims: Transforming the Generation and Adoption of PCOR in Practice (T-GAPP).T-GAPP is designed to advance the nation's leadership capacity in deploying patient-centered outcomes research within learning health systems (LHS). The specific aim of the program is to recruit and train future leaders in patient centered outcomes research (PCOR)methods and conduct PCOR research in a LHS.

Overlap: None

Title: Using patient centered data and behavioral economics to improve physical conditioning, mobility, and healthcare utilization after radical cystectomy (PI:Daniel J Lee)

Time Commitments:

Supporting Agency: NIA Research Centers Collaborative Network, U24AG058556 – RFA for Behavioral Change to Benefit Older Adults

Address: 251 Bayview Blvd, Baltimore, MD 21224

Contracting/Grants Officer: Frank Bandiera

Performance Period: 7/1/ 2019 – 12/31/2021

Level of funding:

Project Goals and Aims: Randomized-controlled trial of behavioral economics approaches (gamefication and social incentives)to increase mobility (daily step counts) in patients with bladder cancer undergoing radical cystectomy at the Hospital of the University of Pennsylvania.

Overlap: None

Title: Connected Health and Population Health Improvement (PI: Lee)

Time Commitments: 1.2 calendar

Supporting Agency: Institute for Translational Medicine and Therapeutics (ITMAT; Penn CTSA)

Address: 3400 Civic Center Blvd, Philadelphia, PA 19104

Contracting/Grants Officer: Andrea Albelda

Performance Period: 6/01/2019 – 12/31/2021

Level of funding:

Project Goals and Aims: Support for projects (Identifying Health Mobility Targets and Changing Behavior in Hospitalized Seniors)by use of Way To Health research platform.

Overlap: None

Level of Funding:

Project Goals: This project will analyze chimeric antigen receptor (CAR)-modified T cells from patient cohorts to identify the lentiviral vector genomic integration sites associated with optimal in vivo CAR T cell proliferation, persistence, and function, and characterize genetic loci that might be directly targeted to enhance CAR T cell therapeutic efficacy.

Overlap: None

PI: Rick Bushman (MPI)

Role: Co-Investigator

Project Title: Engineering the next generation of T cells

Time Commitment: 1.07

Supporting Agency: NCI/NIH/DHHS (NATIONAL INSTITUTES OF HEALTH)

Sponsor Award Number: 1-U54-CA-244711-01

Agency Contact: SONG, MIN-KYUNG H

Performance Period: 09/25/2019 - 08/31/2024

Level of Funding:

Project Goals: The purpose of this U54 is to employ immuno-engineering principles to design more durable, accessible, and less toxic immunoprevention and immunotherapy strategies. The focus of our U54 entitled "Engineering the next generation of T cells" is on developing next-generation gene-editing or modification of immune cells to improve persistence in vivo, control and manipulate the immune system to reduce off-target toxicities and enhance anti-tumor effectiveness of adoptive cell therapy.

Overlap: None

PI: Carl June

Role: Co-Investigator

Project Title: The role of microenvironment mechanics in sarcoma immune evasion

Time Commitment: 0.96

Supporting Agency: DEPARTMENT OF THE ARMY

Sponsor Award Number: W81XWH2110757

Agency Contact: <https://www.grants.gov/web/grants/support/program-management-office.html>

Performance Period: 08/01/2021 - 07/31/2024

Level of Funding:

Project Goals: Our objective is to understand the role of Collagen VI in immune evasion towards the development of novel approaches that improve the therapeutic efficacy of checkpoint blockade. Importantly, this work will provide a methodological and conceptual foundation to understand the role of matrix proteins in CD8+ T cell function in solid tumors. We anticipate that translation of our findings to the sarcoma clinic could take five years or less.

Overlap: None

PI: TZIPORA S EISINGER

Role: Co-Investigator

Project Title: Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome

Time Commitment: 0.6

Supporting Agency: NIH (Johns Hopkins)

Sponsor Award Number: U01CA247576-03

Agency Contact: MCCARTHY, SUSAN A

Performance Period: 01/2020 - 12/2024

Level of Funding:

Project Goals: To determine how catecholamines modulate macrophage function and cytokine release induced by CART cells in mice and human.

Overlap: None

PI: Staedtke, Verena

Role: Co-Investigator

Project Title: Pan-heme" CAR Anti-CD38 CAR T cells for myeloid, lymphoid and plasma cell malignancies

Time Commitment: 0.6

Supporting Agency: The Leukemia & Lymphoma Society, Inc

Sponsor Award Number: 7022-20

Agency Contact:

Performance Period: 10/2019 - 09/2024

Level of Funding:

Project Goals: This SCOR has integrated translational projects with a focus on CD38, a validated target in hematologic malignancies. The overarching design of this SCOR is inherently synergistic: Biological tools and financial resources will be pooled to develop a single, effective approach to treat 3 different hematologic malignancies across a spectrum of age ranges.

Overlap: None

PI: June, Carl

Role: Co-Investigator

Project Title: Mutation-based clonal evolution and aging of T cells and CAR T cells in late-in-life B cell cancers

Time Commitment: 1.2

Supporting Agency: SAMUEL WAXMAN CANCER RESEARCH FOUNDATION

Sponsor Award Number: N/A

Agency Contact: William Stillman

Performance Period: 10/01/2022 - 09/30/2025

Level of Funding:

Project Goals: We propose to use new single-cell profiling technology that identifies mutations associated with CAR T cell aging to identify mutated genes and their modulation of

cell growth, providing a better understanding of the precise molecular defects and routes to improving CAR T cell therapy in the aging patients.

Overlap: none

PI: June, Carl

Role: Co-Investigator

Project Title: Developing Engineered Cell Therapies for Metastatic Castrate Resistant Prostate Cancer to Increase Efficacy and Decrease Toxicity

Time Commitment: 1.92

Supporting Agency: PROSTATE CANCER FOUNDATION

Sponsor Award Number: 22TACT03

Agency Contact:

Performance Period: 02/10/2023 - 02/09/2026

Level of Funding:

Project Goals: The long-term goals of this Consortium are to develop next generation immunotherapies with engineered T Cells and to translate the research into new therapies with curative potential for patients with metastatic castrate-resistant prostate cancer.

Overlap: none

PI: June, Carl

Role: Co-Investigator

Project Title: Translating Data into Insights and Digital Products

Time Commitment: 0.96 ca months

Supporting Agency: DANAHER INNOVATION CENTER, LLC

Sponsor Award Number: N/A

Agency Contact: Jennifer Moody

Performance Period: 12/27/2022 - 12/27/2024

Level of Funding:

Project Goals: We will focus on performing correlative analyses and developing data science pipelines to inform precision CAR T cell therapies, combining the power of biomarker-based patient matching with the immense potential of CAR T cells to create novel, safe and curative therapies. The goal will be to develop algorithms that can prospectively identify those patients whose disease is likely to respond to novel therapies. We will do this via analysis of existing data sets and newly generated data sets from archived samples.

Overlap: None

Role: PI

Project Title: Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19

Time Commitment: 1.56 CM

Supporting Agency: NIH

Sponsor Award Number: 2P01CA214278-06A1

Agency Contact: Meininger, Jennifer

Performance Period: 09/19/2023 – 08/31/2028

Level of Funding:

Project Goals: The central hypothesis is that by combining two orthogonal technologies – CAR T cells and human genome editing with CRISPR/Cas9 – to overcome the limitations and vulnerabilities of each individual technology.

Designing CART cells that are more efficacious, safer, and more widely available than earlier generations. Long-term-goals are to produce “universal CAR T” from a variety of input cell sources, addressing a critical barrier to the field.

Overlap: None

Role: **Project 1 Lead**

PI: June, Carl

Project Title: Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19

Time Commitment: 1.2 CM

Supporting Agency: NIH

Sponsor Award Number: 2P01CA214278-06A1

Agency Contact: Meininger, Jennifer

Performance Period: 09/19/2023 – 08/31/2028

Level of Funding:

Project Goals: The central hypothesis is that by combining two orthogonal technologies – CAR T cells and human genome editing with CRISPR/Cas9 – to overcome the limitations and vulnerabilities of each individual technology. Designing CART cells that are more efficacious, safer, and more widely available than earlier generations. Long-term-goals are to produce “universal CAR T” from a variety of input cell sources, addressing a critical barrier to the field.

Overlap: None

PI: June, Carl

Role: **Co-Leader of Core C**

Pending Support

Project Title: Optimizing CART therapy: from vector insertional mutagenesis to clinical gene editing tools.

Time Commitment: 1.8

Supporting Agency: NATIONAL INSTITUTES OF HEALTH

Sponsor Award Number: N/A

Agency Contact

Performance Period: 07/01/2024 - 06/30/2029

Level of Funding:

Project Goals: The goal of the project is to characterize insertional mutagenesis by lentiviral vectors in CART therapy, then use this information to inform follow up functional studies. Completion of the project will yield genes and pathways to modulate to optimize CART therapy.

Overlap: None
Role: MPI (Contact PI)

Previous Support

Project Title: Unraveling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

Time Commitment: 0.60

Supporting Agency: V FOUNDATION FOR CANCER RESEARCH

Sponsor Award Number: DC2019-042

Agency Contact: Shane Jacobson, Chief Executive Officer

Performance Period: 11/01/2019 - 11/01/2023

Level of Funding:

Project Goals: In this project, we will leverage the unique collaborative expertise of investigators in cancer genetics and precision medicine, antibody phage display, translational immunotherapeutics and canine immunotherapy clinical trials at the University of Pennsylvania's Schools of Veterinary Medicine and Medicine. Collectively, we aim to further our understanding of the mutational load of canine urothelial carcinoma and identify correlative biomarkers that predict response and resistance to combination checkpoint inhibition.

Overlap: None

PI: MASON, NICOLA

Role: co-Investigator

Project Title: Determining On-target, Off-site Toxicity of Anti-Tn-MUC1 CAR T cells

Time Commitment: 0.01

Supporting Agency: TMUNITY THERAPEUTICS, INC

Sponsor Award Number: Tmunity SRA 11

Agency Contact: Sujay Kango, <https://www.tmunity.com/management>

Performance Period: 11/1/18 – 12/8/22

Level of Funding:

Project Goals: In this project, we will test whether Tn-MUC1-targeted CAR T cells are active against a panel of normal cells. Following detection of Tn-Muc1 protein expression in primary cells derived from various normal tissues, anti-Tn-Muc1 CAR T cells will be co-cultured with these tissue-derived cells to determine potential on-target, off-site toxicity.

Overlap: None

PI: JUNE, CARL H

Role: co-Investigator

Project Title: Overcoming CAR T cell Resistance using Next-generation Immuno-engineering.

Time Commitment: 0.1

Supporting Agency: Tmunity Therapeutics, Inc.

Sponsor Award Number: SRA 16

Agency Contact: Sujay Kango, <https://www.tmunity.com/management>

Performance Period: 4/1/19 – 12/8/22

Level of Funding:

Project Goals: Our goal is to employ genetic and cellular engineering principles to design more potent CAR T cells resistant to intrinsic and extrinsic dysfunction. This project is expected to open therapeutic horizons in the field of adoptive immunotherapy and offer new research prospects that could be translated to improving treatment of many different cancers.

Overlap: None

Role: PI

Project Title: Tmunity Therapeutics, Inc. SRA 20

Time Commitment: 0.01

Supporting Agency: Tmunity Therapeutics, Inc.

Sponsor Award Number: SRA 20

Agency Contact: Sujay Kango, <https://www.tmunity.com/management>

Performance Period: 2/5/21 – 8/31/23

Level of Funding:

Project Goals: This project will establish a comprehensive strategy to target the major limitations in CAR T cell therapy, increasing the feasibility of this already transformational approach. In this vein, we will use an innovative genetic knock-in approach to express multiple CARs (i.e., a “CAR fleet”) and other payloads (dnTGFβRII, PD-1/CD28 switch receptor) in T cells, while simultaneously disrupting negative regulators of proliferation, anti-tumor function or genes crucial for allogeneic rejection.

Overlap: None

PI: JUNE, CARL H

Role: co-Investigator

Project Title: Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRA, TCRB, and PD-1

Time Commitment: 0.0

Supporting Agency: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY

Sponsor Award Number: UPCC 25416

Agency Contact: Janine Pixley

Performance Period: 02/01/2018 - 03/31/2021

Level of Funding:

Project Goals: The primary goals of the study are to determine the safety of NYCE T cells in relapsed and/or refractory MM, sarcoma, and melanoma patients.

Overlap: None

Role: Investigator

Project Title: Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCR α , TCR β , and PD-1 (UPCC# 25416)

Time Commitment: 0.0

Supporting Agency: TMUNITY THERAPEUTICS, INC

Sponsor Award Number: Tmunity Therapeutics, Inc.

Agency Contact: Rachael Caldwell

Performance Period: 02/01/2018 - 03/31/2021

Level of Funding:

Project Goals: The primary goals of the study are to determine the safety of NYCE T cells in relapsed and/or refractory MM, sarcoma, and melanoma patients.

Overlap: None

Role: Investigator

Project Title: Inhibition of BET Bromodomain Proteins Reverses Chimeric Antigen Receptor (CAR) Silencing and Reinvigorates Hypofunctional T Cells

Time Commitment: 0.01

Supporting Agency: Levis Family Leukemia Research Award

Sponsor Award Number: Levis Family Leukemia Research Award

Agency Contact: N/A

Performance Period: 10/1/18 – 9/30/22

Level of Funding:

Project Goals: The goal of this study is to reverse silencing of CARs by pharmacologically targeting BET bromodomain “readers” of histone acetylation marks. In addition, we will assess the impact of BET bromodomain protein antagonists on the function of gene-modified T cells used for adoptive cell therapy.

Overlap: None

Role: Co-PI

Project Title: Overcoming Resistance of Acute Lymphoblastic Leukemia to Chimeric Antigen Receptor (CAR) T Cell Therapy

Time Commitment: 0.24

Supporting Agency: GABRIELLE'S ANGEL FOUNDATION

Sponsor Award Number: N/A

Agency Contact: Jennifer Ranieri, Executive Director

Performance Period: 07/01/2018 - 06/30/2020

Level of Funding:

Project Goals: This research focuses on the development of a novel multi-pronged approach to overcome resistance of ALL to CAR T cell therapy using next-generation genome editing tools to endow T cells with CARs directed against multiple target antigens, while simultaneously disrupting negative epigenetic regulators of CAR T cell proliferative capacity and anti-tumor activity.

Overlap: None

Role: PI

Project Title: Multiplexed CRISPR editing of T cells through large cargo delivery via mechanoporation

Time Commitment: 0.12

Supporting Agency: GEORGIA INSTITUTE OF TECHNOLOGY (NSF)

Sponsor Award Number: AWD-102507-G1

Agency Contact: Todd Sulchek

Performance Period: 02/01/2020 - 07/31/2021

Level of Funding:

Project Goals: The goal of this research project is to test a microfluidic cell transfection technology with the potential to permit multiple CRISPR edits with high transfection efficiency and viability.

Overlap: None

PI: Todd Sulchek

Role: co-Investigator

Project Title: Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer

Time Commitment: 0.01

Supporting Agency: STAND UP TO CANCER

Sponsor Award Number: SU2C #RT6162

Agency Contact: Alice Lustig

Performance Period: 02/01/2019 - 11/30/2022

Level of Funding:

Project Goals: The overarching scientific theme of our Project is to molecularly define the pathways that promote durability of human CAR T cell function and/or checkpoint blockade effects using state of the art profiling technologies and an array of relevant models to probe factors that enable CAR T cells to maintain high levels of activity for prolonged periods of time.

Overlap: None

PI: Carl H June

Role: co-Investigator

Project Title: Metabolic Reprogramming of the CAR-T Cell Epigenome

Time Commitment: 1.2

Supporting Agency: ALLIANCE FOR CANCER GENE THERAPY

Sponsor Award Number: N/A

Agency Contact: Main Site

Performance Period: 09/01/2019 – 07/1/2023

Level of Funding: 2

Project Goals: This study will establish a firm mechanistic link between changes in metabolic input to the adaption of the CAR T cell epigenome. Identification of the molecular switches modulated by metabolic cues that can turn epigenetic checkpoints on and off will provide new CAR T cell augmentation strategies, which can be rapidly translated into clinical trials.

Overlap: None

Role: PI

Project Title: Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19

Time Commitment: 1.8

Supporting Agency: NIH

Sponsor Award Number: P01CA214278-05

Agency Contact: SONG, MIN-KYUNG H

Performance Period: 08/2017 – 07/2023

Level of Funding:

Project Goals: Our goal is to develop next generation immunotherapy for hematologic malignancies which strike more than 200,000 people every year in the United States. Our approach involves the development of next generation therapies with chimeric antigen receptor (CAR) T cells, involving innovative combinations of CAR T Cells and generic editing with CRISPR/Cas9 technology to be tested in four clinical trials.

Overlap: None

PI: JUNE, CARL H

Role: co-Investigator

Lal, Priti

Current

Title: Multi-omic Biomarker Discovery and Validation in Heart Transplant Patient Populations (R01AI144522-01A1 Keating, Co-I)

Time Commitments: 1.08 CM

Supporting Agency: NIH/NIAID

Address:

5601 Fishers Ln, Rockville,
MD 20852

Contracting/Grants Officer: ROBIEN, MARK ANDREW

Performance Period: 3/1/20-2/28/25

Level of funding:

Project Goals: The overarching aim is to use multi-omics profiling, which spans genomics, transcriptomics, proteomics and metabolomics profiling of biospecimens collected at prospective timepoints from cardiac patient's post-transplantation, for discovery and validation of prognostic and diagnostic biomarkers of post-transplantation complications

Specific Aims: We aim to diagnose and prognosticate acute allograft rejection and to assess the impact of biomarkers of post-transplantation complications including acute rejection, from the various omics across using 'integrative personal omic profiling' (iPOP) developed by investigators in our team. We outline a transformation advance in the molecular diagnoses of acute cardiac allograft rejection within the formalin-fixed paraffin embedded (FFPE) heart allograft biopsy samples, which may change the current standard-of-care which uses conventional histopathology grading alone. We will also assess how genetic polymorphisms impact other omic profiles in the same-, and in subsequent-, timepoints from the same individuals through to post-transplantation complex phenotypes such as acute rejection. We aim to investigate how genetic variants in the HLA and minor histocompatibility (mHA) regions impact clinically relevant post-transplantation outcomes including acute rejection and patient survival.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Title: Role of MED1 in the AR-dependent transcription in advanced prostate cancer (R01CA249210 Asangani, Co-I)

Time Commitments: 0.6 CM

Supporting Agency: NIH/NCI

Address:

9000 Rockville Pike
Bethesda, MD 20892

Contracting/Grants Officer: FINGERMAN, IAN M

Performance Period: 4/1/20-3/31/25

Level of funding:

Project Goals: The goal of this project is to explore the role of CDK7 mediated phosphorylation of MED1 in the formation and stability of MED1-AR complex and AR signaling in advanced prostate cancer.

Specific Aims: The three specific aims of the projects are: Specific Aim 1: Investigate the role of p-MED1 in hyper-activation of AR-signaling Specific Aim 2: Investigate the mechanism of increased p-MED1 in enzalutamide refractory PCa. Specific Aim 3: Establish the efficacy of CDK7 inhibitor in clinically relevant naïve and refractory CRPC models in vivo.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Title: University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award (Haas, Co-I)

Time Commitments: 0.36 CM

Supporting Agency: DOD

Address:

1120 Fort Detrick
Frederick, MD, 21702

Contracting/Grants Officer: Amie Bunker

Performance Period: 9/15/20-9/14/24

Level of funding:

Project Goals: Review and subtype Renal cell carcinoma accrued in this clinical trial

Specific Aims: Aim 1: Design innovative clinical trials for the KCRC

Aim 2. Accrue at least 25 patients per year to KCRC trials

Aim 3. Perform translational research on samples obtained from KCRC trials

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Title: Computer-Assisted Histologic Evaluation of Cardiac Allograft Rejection (1R01HL151277 Margulies, Co-I)

Time Commitments: 0.24CM

Supporting Agency: NIH/NHLBI

Address:

31 Center Drive

Bethesda, MD 20892

Contracting/Grants Officer: LUO, JAMES

Performance Period: 9/1/20-8/31/24

Level of funding:

Project Goals: Though cardiac transplantation is a lifesaving intervention, cardiac allograft rejection (CAR) remains a relatively common and serious complication that confers an increased risk of acute graft failure and adverse patient outcomes. For three decades, endomyocardial biopsy (EMB) with histological grading, as recommended by the International Society of Heart and Lung Transplantation (ISHLT) has been the broadly applied standard for CAR diagnosis. However, it is widely appreciated that the ISHLT rejection grading standard lacks diagnostic accuracy and has limited ability to discern the mechanism of rejection. These limitations expose patients to risks of both over-treatment and under-treatment, and highlight the unmet need for more accurate and informative approaches to histopathologic analysis of EMB samples. Our team is a leader in computational pathology image analysis with over 200 papers and >30 issued patents in this area. We have already developed and evaluated a computer assisted histopathology grading evaluation (CACHE) scheme which (1) in N=205 patients, had an area under the receiver operating characteristic curve (AUC)=0.95 compared to two cardiac pathologists (mean AUC=0.74) in distinguishing normal from failing hearts and (2) could distinguish low and high ISHLT rejection grades in N=1109 patients with a performance that exceeds that of trained cardiac pathologists. Recognizing the frequent discordance between ISHLT rejection grade and the clinical trajectory of a rejection event, we will further develop and optimize CACHE to identify new “grade agnostic” morphologic biomarkers of clinically serious CAR. Our scientific premise is that morphologic biomarkers prioritized based on their correlation to patients’ clinical trajectories and underlying immunological disease mechanisms will generate an accurate, consistent and informative classifier for diagnosing allograft rejection. In service of this hypothesis, the proposed research will address three specific aims.

Specific Aims: Aim 1, we will utilize computational image analysis to discover the morphologic biomarkers of rejection-related injury which are needed to develop a classifier capable of assessing the clinical trajectory of CAR. In Aim 2, we will provide mechanistic annotation of biomarkers identified in Aim 1 through correlation with in-situ immunologic markers using custom multi-parameter immunofluorescence panels. In Aim 3, we employ a multicenter, prospective cohort to validate the diagnostic and mechanistic accuracy of the new rejection classifier developed in Aims 1 and 2. Ultimately, development of a more accurate and mechanistically informative tool for morphologic diagnosis of CAR will improve patient outcomes by reducing over- and under- treatment and inspire applications in other organ transplants. Interestingly, development of a superior histologic diagnostic tool will empower development of alternative, biopsy-free diagnostic approaches that have been handicapped by the necessity of comparison with the flawed ISHLT rejection grade as a reference standard.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Project Title: Prognostic and Predictive morphometric risk score for aggressive prostate cancer (Madabhushi, Co-I)

Time Commitment: 1.2 CM

Supporting Agency: NIH/NCI

Sponsor Award Number: R01CA268287

Agency Contact: MCKEE, TAWNYA C

Address:

9000 Rockville Pike

Bethesda, MD 20892

Performance Period: 7/1/22-7/30/27

Level of Funding:

Project Goals: Using AI algorithms, we will analyze images from routinely performed H&E sections to predict outcomes of prostate cancer.

Specific Aims: In this R01, we will validate IRiS as (1) prognostic of BCR and risk of metastasis as well as (2) predictive of the added benefit of additional chemotherapy following definitive therapy (surgery or radiation) in PCa. In a recent paper in Clin Cancer Res, we identified IRiS specific prognostic features for African American (AA) men with PCa. We will build on these findings to develop population specific IRiS models for PCa. We will also further optimize IRiS by including (1) features of stromal and cribriform morphology, (2) develop population specific IRiS models for different ethnic groups, and (3) complement IRiS with clinico-pathological features.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Project Title: Protein kinase C signaling in prostate cancer health disparities (Kazanietz, Co-I)

Time Commitment: 0.60 CM

Supporting Agency: NATIONAL CANCER INSTITUTE/NIH/DHHS

Sponsor Award Number: 1 R01 CA276082-01

Agency Contact: Gril, BRUNILDE M

Address: 9000 Rockville Pike

Bethesda, MD 20892**Performance Period:** 06/08/2023- 05/31/2028

Level of Funding:

Project Goals: In this proposal we will investigate the involvement of protein kinase C alpha in prostate tumorigenesis, and whether signaling mediated by this kinase has a role in prostate cancer racial disparities.

Specific Aims: **Specific Aim 1: To establish PKCa as a marker of racial disparities in human prostate cancer.** We will take advantage of a large collection of primary and metastatic human PCa tumors available to the P.I., both from AA and EA men. Using an IHC approach, we will test the hypothesis that there is disproportionate PKCa expression and/or activation in AA PCa. In addition, we will examine whether PKCa expression/hyperactivation co-localizes with markers of invasiveness within the tumors. A racial-dependent categorization analysis based on Gleason score, disease recurrence, and metastasis will be pursued.

• **Specific Aim 2: To establish the *in vivo* functional relevance of PKCa in prostate tumorigenesis and metastasis.** First, we will generate syngeneic, doxycycline-inducible mouse PCa cell lines of “*Low PKCa*” and “*High PKCa*” expression, using RNAi silencing and overexpression (WT and constitutively active PKCa), respectively. Tumor growth and metastasis will be evaluated upon orthotopic cell implantation in prostates of immunocompetent mice. Second, we will examine if genetic deletion of the PKCa gene (*PRKCA*) impairs the spontaneous formation of prostate tumors and metastasis in the PCa TRAMP mouse model. Third, we will use a pharmacological approach *in vivo* (PKCa inhibitor) to authenticate data generated in syngeneic and genetic mouse models, and set proof-of-principle for therapeutics.

• **Specific Aim 3: To determine the relevance of prostate cancer cell PKCa in the control of the tumor immune landscape and gene expression.** To understand mechanistically PKCa-driven disparities, we will thoroughly characterize immune cell populations and cytokine production upon inducible PKCa silencing in mouse prostate tumors. This will provide a comprehensive perspective on how cancer cell PKCa contributes to generate a pro-inflammatory and immunosuppressive landscape that is a hallmark of PCa in AA men. In addition, PKCa-driven genetic networks in mouse tumors will be established via transcriptome analysis, which will be integrated with human databases to identify prospective racial differences in PKCa-regulated signaling.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Pending

Project Title: Diacylglycerol signaling in aggressive prostate cancer (Kazanietz, Co-I)

Time Commitment: 0.6 CM

Supporting Agency: DOD

Sponsor Award Number: NA

Agency Contact: NA

Performance Period: 7/1/23-6/30/26

Level of Funding:

Project Goals: We propose to define the biology of prostate cancer progression to lethal prostate cancer to reduce death and Advance health equity and reduce disparities in prostate cancer.

Specific Aims: **SPECIFIC AIM 1:** To establish the *in vivo* functional relevance of aberrant DAG/PKCa signaling in prostate tumorigenesis and metastasis using xenografts and genetically-engineered mouse models.

Hypothesis: Our preliminary results compellingly established the requirement of PKCa for the proliferative and tumorigenic activities of aggressive PCa cells, as well as for migration/invasion. We hypothesize that PKCa is

crucial for the maintenance of the tumorigenic phenotype and metastasis. To unambiguously address this issue, we will use three complementary approaches: a) a syngeneic mouse model whereby TRAMP-C2 PCa cells⁹¹⁻⁹⁴ will be engineered to modulate PKCa expression in an inducible-manner and implanted (Aim 1.A); b) a widely used autochthonous model - Transgenic Adenocarcinoma Mouse Prostate (TRAMP)⁹⁵⁻⁹⁷ - that will be made null for PKCa (Aim 1.B); and c) a pharmacological approach for PKCa inhibition in TRAMP models (Aim 1.C).

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Project Title: Addressing Prostate Cancer Disparities in African Americans through Precision Oncology- Project 2

Time Commitment: 0.6 CM

Supporting Agency: NCI/NIH

Sponsor Award Number: P50CA265799

Agency Contact: NA

Performance Period: 07/01/2023-60/30/2028

Level of Funding:

Project Goals: We will review the morphologic, molecular and immune markers associated with aggressive behavior of prostate cancer in men of African descent.

Specific Aims: The SPORE will undertake research to achieve the following Specific Aims:

Aim 1: Discover mechanisms and biomarkers in PCa that can be translated into precision oncology therapies targeted to AAM.

Aim 2: Translate these discoveries into clinical modalities that ensure optimal therapeutic responses and avoid the generation or exacerbation of PCa disparities.

Aim 3: Create mechanisms and interactions with the broader community to have a public health impact on PCa disparities in AAM.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Project Title: Addressing Prostate Cancer Disparities in African Americans through Precision Oncology- Core B: Pathology and Biomarker Core (PBC)

Time Commitment: 0.6 CM

Supporting Agency: NCI/NIH

Sponsor Award Number: P50CA265799

Agency Contact: NA

Performance Period: 07/01/2023-60/30/2028

Level of Funding:

Project Goals: Dr Lal will be the central reviewer for all the prostate cancer cases. She will be leading the construction of TMAs. She will be leading the IHC initiative and collection of data for the projects of the SPORE.

Specific Aims: The SPORE will undertake research to achieve the following Specific Aims:

Aim 1: Discover mechanisms and biomarkers in PCa that can be translated into precision oncology therapies targeted to AAM.

Aim 2: Translate these discoveries into clinical modalities that ensure optimal therapeutic responses and avoid the generation or exacerbation of PCa disparities.

Aim 3: Create mechanisms and interactions with the broader community to have a public health impact on PCa disparities in AAM.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Previous

Title: Exploiting Cholesterol Metabolism to Treat Primary and Metastatic Renal Carcinoma W81XWH2010856 (Simon, Co-I)

Time Commitments: 0.25 CM

Supporting Agency: DOD

Address:

1120 Fort Detrick

Frederick, MD, 21702

Contracting/Grants Officer: Thomas Winter

Performance Period: 9/1/20-9/29/22

Level of funding:

Project Goals: The objectives of this project are to explore the roles of SCARB1 and HSD3B7 in the accumulation of cholesterol and cholesterol esters in clear cell renal carcinoma, with the goal to inhibit both pharmacologically for improved treatment of this disease.

Specific Aims: Aim 1A: Evaluation of SCARB1 effects on orthotopic and metastatic ccRCC

Aim 1B: Translating SCARB1 inhibition into future ccRCC treatments

Aim 1C: Defining the mechanistic basis of SCARB1 effects on ccRCC cell growth

Aim 2A: Evaluation of HSD3B7 effects on orthotopic and metastatic ccRCC

Aim 2B: Defining the mechanistic basis of HSD3B7 inhibition-mediated ccRCC cell death

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

Project Title: Precision Interception of Aggressive Prostate Cancer in African American Men

Time Commitment: 0.1572

Supporting Agency: DANA-FARBER CANCER INSTITUTE (NATIONAL CANCER INSTITUTE/NIH/DHHS)

Sponsor Award Number: 5P20CA233255-03

Address: 9000 Rockville Pike

Bethesda, MD 20892

Agency Contact: Justin Birken

Performance Period: 09/01/2021 - 08/31/2022

Level of Funding:

Project Goals: This project will evaluate the tumor microenvironment of prostate cancer and outcomes. Additionally this project will develop an image data base for application of AI algorithms for identification of aggressive features.

Specific Aims: Summary The mission of the proposed P20 is to reduce and eliminate disparities in prostate cancer (PCa) mortality among African American (AA) men by developing and implementing strategies that will (1) optimize therapeutic approaches, (2) generalize precision medicine approaches, and (3) implement and disseminate optimal therapeutic approaches for AA men with PCa. To achieve these goals, this P20 proposal will build on the “Men of African Descent and Carcinoma of the Prostate” (MADCaP) network that has developed infrastructure and data to address disparities in PCa in AA men. The team assembled here has previously collaborated to develop translational research that is led by established basic and clinical experts who have worked together to develop each concept. The result is a novel inter-disciplinary collaboration with the potential to maximize clinical impact on PCa disparities in AA men. The Administration Core will support three projects as well as the Biosample and Biomarker Core. The Administration Core will also coordinate the oversight activities of the External Advisory Board (the Community, Clinical, and Scientific Advisory Board, CCSAB) and the Steering Committee comprised of all project and core leaders. The CCSAB in turn will oversee the selection and monitoring of the Developmental Research Project (DRP) component. These DRPs will foster “collective Impact” research that refers to the commitment of a group of important actors from different sectors to adopt a common agenda for solving a specified problem. These collective impact developmental pilots will work in parallel with the three research projects to foster research of the highest quality and potential for clinical applications, inspire groundbreaking ideas, and to promote the transition of pilot studies with the highest translational potential into a full SPORE application after three years. Finally, the Administration Core will work with three partners that bring substantial resources toward the success of this proposal. These resources are (1) The Dana Farber Harvard Cancer Center (DFHCC) SPORE in Prostate Cancer; (2) the DFHCC Initiative to Eliminate Cancer Disparities; and (3) the MADCaP Implementation Network (MADCaP-IN) that includes community and inner city clinics that see a substantial proportion of AA PCa cases in Boston, Philadelphia, and Tampa, as well as linkages to the Walter Reed Army Hospital through the Center for Prostate Disease Research. The MADCaP-IN will serve as the centers for research participant accrual as well as centers for the implementation of current and future clinical research.

Overlap: No scientific or budgetary overlap with the proposed PRMRP

Title: Race Specific 3D Computational Pathology Biomarkers for Predicting Prostate Cancer Specific Recurrence (Madabhushi, Co-I)

Time Commitments: 0.12 CM

Supporting Agency: DOD

Address:

1120 Fort Detrick

Frederick, MD, 21702

Contracting/Grants Officer: Mirlene Andou

Performance Period: 1/1/20-12/31/22

Level of funding:

Project Goals: In this Prostate Cancer Health Disparity grant we seek to develop a computational risk-assessment tool (PRISM3D) based off computer extracted features from surgical specimens which are scanned by the novel 3D OTLS technology. The objectives of this project are two-fold. Firstly, to combine the power of OTLS and 3d computational pathology to discern morphologic differences between the PCa phenotype in AA and CA men with PCa. Secondly to use these features to develop the PRISM3D computational assay in order to separately predict outcome (biochemical recurrence and metastasis) in AA and CA men. PRISM3D will explicitly learn and account for biological and morphological differences in the PCa phenotype between AA and CA men via the 3D digitized tissue volumes rendered via the tissue non-destructive OTLS technology. This project is aligned with the FY19 PCRP overarching challenge to reduce lethal prostate cancer in African Americans, as PRISM3D would enable (1) early and accurate identification of AA men with PCa who would be candidates for adjuvant therapy following surgery while also (2) identifying AA men with lower risk PCa who could avoid adjuvant therapy

Specific Aims: We propose to develop and validate the Prostate Cancer Race-specific Image Score using CoMputational 3D pathology (PRISM3D) prognostic assay. The goal of PRISM3D, evaluated on digitized radical prostatectomy specimens, will be to predict PCa outcome following surgical resection. Study aims are as follows.

Overlap: No scientific or budgetary overlap with the proposed PRMRP proposal

OTHER SUPPORT

Name of PI: Ronac Mamtani

Commons ID: MAMTANI

ACTIVE

Title: **(UPCC 09818): An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer**

Major Goals: To study efficacy of enfortumab versus single agent chemotherapy in urothelial cancer

Project Number: Mamtani-7465-CL-301

Source of Support: ASTELLAS PHARMA INC

Name of PD/PI: Mamtani, Ronac

Role: PI

Sponsor Contact: Kyla Billings

Primary Place of Performance: University of Pennsylvania

Project Period: 09/11/2018 - 06/30/2024 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2024
Effort	0.24 Cal.

Title: ***Leveraging Real-World Data to Optimize Immune-checkpoint Blockade in Metastatic Urothelial Cancer (mUC)***

Major Goals: **Aim 1:** To understand the immunotherapy (IO) landscape in metastatic urothelial cancer (mUC)

Aim 2: To describe real-world (rw) evidence of first-line (1L) IO (overall IOs and by agent) effectiveness

Aim 3: To determine optimal treatment sequence in initiators of chemotherapy or IO

Aim 4: To identify subpopulations that might benefit the most from pembrolizumab or chemotherapy

Source of Support: MERCK & CO., INC

Name of PD/PI: Ronac mantani

Role: PI

Sponsor Contact: Haojie Li

Primary Place of Performance: University of Pennsylvania

Project Period: 9/11/20-06/30/24 Total Award Amount: Person

Months (Calendar/Academic/Summer) per budget period.

Year	2024
Effort	2.80 Cal.

Title: ***University of Pennsylvania Clinical Trial Site Application for Kidney Cancer Research Consortium Award***

Major Goals: Aim 1: Design innovative clinical trials for the KCRC; Aim 2. Accrue at least 25 patients per year to KCRC trials; Aim 3. Perform translational research on samples obtained from KCRC trials.

Project Number: UT MDACC

Source of Support: Department of Army

Name of PD/PI: Haas

Role: Co-Investigator

Sponsor Contact: Amie Bunker

Primary Place of Performance: University of Pennsylvania

Project Period: 9/15/20-9/14/24 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023	2024
Effort	0.36 Cal.	0.36 Cal.

Title: **(UPCC 13822): A Non-Interventional Retrospective Real-World Study to Assess Treatment Patterns, Surrogate Endpoints & Overall Survival in Muscle Invasive Bladder Cancer**

Major Goals: Among patients who underwent RC + PLND (with or without neoadjuvant chemotherapy) as their initial treatment for MIBC:

To describe the baseline demographic, clinical, and disease characteristics

OTHER SUPPORT

Name of PI: Ronac Mamtani

Commons ID: MAMTANI

To describe treatment patterns overall and by patient characteristics

To describe clinical outcomes overall and by patient characteristics and/or treatment options (e.g., patients who received vs. did not receive neoadjuvant chemotherapy, cisplatin eligible vs ineligible patients) In addition, as a secondary objective, the study will also explore to assess the strength of association of surrogate endpoints with OS and EFS.

Project Number: EPO5026.049/VEAP 7977-004- Mam

Source of Support: MERCK & CO., INC.

Name of PD/PI: Mamtani, Ronac

Role: PI

Sponsor Contact:

Primary Place of Performance: University of Pennsylvania

Project Period: 9/16/22-9/15/23 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023
Effort	0.48 Cal.

Title: **A Real-Time Digital Repository to Evaluate Cancer Therapies Granted Accelerated Approval (AA) by the Food and Drug Administration (FDA)**

Major Goal: This one-year proposal will construct the largest “living” database of patients receiving oncology drugs granted FDA accelerated approval, to measure the impact of AA policy reform on prescribing patterns and clinical outcomes associated with those drugs.

Project Number: 23-09287

Name of PD/PI: Ronac Mamtani; Ravi Parikh

Sponsor: Arnold Ventures

Sponsor Contact: Katherine Szarama

Primary Place of Performance: University of Pennsylvania

Project Period: 7/1/23-6/30/24 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2024
Effort	2.4 Cal.

PENDING

Title: **Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care**

Major Goals: To characterize the use of genomic testing among patients diagnosed with solid tumors and to determine how testing and test results impact treatment, survival, and costs of care.

Project Number: 1R01CA280359-01A1

Source of Support: NIH through Yale

Name of PD/PI: Cary Gross (Contact); Michaela Dinan

Role: Co-Investigator

Sponsor Contact: Soulos, Pamela

Primary Place of Performance: University of Pennsylvania

Project Period: 9/1/23-8/31/28 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023 -2028
Effort	0.9 Cal.

Title: **Electronic Health Record (EHR)-Embedded Tools to Improve Post-market Safety Evaluation of Novel Cancer Therapies**

Major Goal: **Aim 1:** We will test the timeliness and comprehensiveness of an EHR-embedded PMSE tool to identify severe irAEs, using a cluster-randomized trial of up to ten academic and community sites. **Aim 2:** We

OTHER SUPPORT

Name of PI: Ronac Mamtani

Commons ID: MAMTANI

will measure the incidence of severe irAEs in real-world patients treated with ICIs, using a prospective cohort study in a national network of up to ten academic and community sites.

Project Number: 1U01FD007927-01

Name of PD/PI: Ronac Mamtani (Contact); Ravi Parikh

Sponsor: NIH

Sponsor Contact: Lauda, Mark

Primary Place of Performance: University of Pennsylvania

Project Period: 9/1/23-8/31/26 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2024 -2026
Effort	3.6 Cal.

In-Kind: None

OVERLAP: None

Previous

Title: ***Abramson Cancer Center Support Grant***

Major Goals: Pilot study of tobacco use and treatment outcomes among bladder cancer patients

Project Number: P30 CA016520

Status of Support: Completed

Source of Support: NIH

Name of PD/PI: Robert Vonderheide

Role: Pilot PI

Sponsor Contact: Krzysztof Ptak

Primary Place of Performance: University of Pennsylvania

Project Period: 02/01/2017 – 6/30/19

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2019
Effort	0.1 Cal.

Title: **UPCC 22817: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)**

Project Number: Mamtani-MK-3475-698-00

Status of Support: Completed

Source of Support: MERCK & CO., INC.

Name of PD/PI: Mamtani, Ronac

Role: PI

Sponsor Contact: Mei Chen ; Bart Ziemski

Primary Place of Performance: University of Pennsylvania

Project Period: 04/17/2018 - 04/16/2020

Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2020
Effort	0.24 Cal.

Title: **UPCC# 13915; Clinical Protocol: APX005M-001 Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors**

Project Number: **822566 Apexigen**

Status of Support: Completed

Source of Support: APEXIGEN INC

Name of PD/PI: Ronac Mamtani

OTHER SUPPORT

Name of PI: Ronac Mamtani

Commons ID: MAMTANI

Role: PI

Sponsor Contact: Xiadong Yang; Bart Ziemski Primary Place of Performance: University of Pennsylvania

Project Period: 07/24/2015-07/23/2018 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2018
Effort	1.2 Cal.

Title: **Insulin resistance in the development and progression of invasive bladder cancer**

Major Goals: This prospective cohort study will address the relationship between insulin resistance in the development and progression of invasive bladder cancer. Importantly, it will serve as an accrual platform for the proposed case- control study.

Project Number: **1K23CA187185-01A1**

Status of Support: Completed

Source of Support:

Name of PD/PI: Ronac Mamtani

Role: PI

Sponsor Contact: Susan E Lim

Primary Place of Performance: University of Pennsylvania

Project Period: 7/01/2015-09/30/2020 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2020	2024
Effort	9 Cal.	Cal.

Title: **Abramson Cancer Center Support Grant**

Major Goals: Pilot-Refining Expectations on Checkpoint inhibitor Outcomes in Underrepresented Populations (RECOUP)

Specific Aim 1: To characterize disparities in enrollment in pivotal clinical trials of immunotherapy for lung, bladder, and renal cancers by comparing clinical characteristics of patients treated with immunotherapy in routine practice vs those enrolled in clinical trials.

Specific Aim 2: To quantify disparities in survival between immunotherapy-treated trial participants, real-world populations, and underrepresented subpopulations (e.g., those with organ dysfunction, poor performance status, and older age).

Specific Aim 3: To determine differences in survival among the underrepresented subpopulations treated with first-line immunotherapy vs (a) the standard of care prior to availability of immunotherapy and (b) no therapy.

Project Number: P30 CA016520

Status of Support: Completed

Source of Support: NIH

Name of PD/PI: Robert Vonderheide

Role: Pilot PI

Sponsor Contact: Krzysztof Ptak

Primary Place of Performance: University of Pennsylvania

Project Period: 03/01/2020-11/30/2020 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2020
Effort	5.1 Cal.

OTHER SUPPORT

Name of PI: Ronac Mamtani

Commons ID: MAMTANI

Title: **(UPCC 22818): Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing**

Major Goals: To study efficacy of chemo-immunotherapy with bladder preservation in bladder cancer.

Project Number: **Mamtani-7465-CL-301** Status of Support: Active

Source of Support: HOOSIER CANCER RESEARCH NETWORK, INC

Name of PD/PI: Mamtani, Ronac Role: PI

Sponsor Contact: Linde Phillips

Primary Place of Performance: University of Pennsylvania

Project Period: 03/07/2019 – 12/31/2022 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	0.24 Cal.

Title: **Retrospective study to characterize Enfortumab Vedotin (EV) users, usage patterns, and treatment sequence: insights from real-world practice**

Major Goals: To characterize real-world treatment patterns of EV.

Project Number: **Mamtani-7465-CL-301** Status of Support: Active

Source of Support: ASTELLAS PHARMA INC

Name of PD/PI: Mamtani, Ronac Role: PI

Sponsor Contact: **Karen Barge**

Primary Place of Performance: University of Pennsylvania

Project Period: 5/10/22-5/10/24 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2023-2024
Effort	4.8 Cal.

Title: **UPCC 24816: MK-3475-361 Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma**

Major Goals: To study efficacy of chemo-immunotherapy versus chemo alone in urothelial cancer.

Project Number: **MK-3475-361-3583** Status of Support: Active

Source of Support: MERCK & CO., INC.

Name of PD/PI: Mamtani, Ronac Role: PI

Sponsor Contact: Tracy Hoggatt

Primary Place of Performance: University of Pennsylvania

Project Period: 10/10/2016-12/31/2022 Total Award Amount:

Person Months (Calendar/Academic/Summer) per budget period.

Year	2022
Effort	1.2 Cal.